rdnt-20250930
0000790526
false
12/31
Q3
2025
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
rdnt:center
rdnt:incentivePlan
rdnt:agreement
rdnt:product
rdnt:customer
rdnt:security
rdnt:jointVenture
rdnt:creditFacility
rdnt:tranche
0000790526
2025-01-01
2025-09-30
0000790526
2025-11-07
0000790526
2025-09-30
0000790526
2024-12-31
0000790526
srt:AffiliatedEntityMember
2025-09-30
0000790526
srt:AffiliatedEntityMember
2024-12-31
0000790526
us-gaap:HealthCarePatientServiceMember
2025-07-01
2025-09-30
0000790526
us-gaap:HealthCarePatientServiceMember
2024-07-01
2024-09-30
0000790526
us-gaap:HealthCarePatientServiceMember
2025-01-01
2025-09-30
0000790526
us-gaap:HealthCarePatientServiceMember
2024-01-01
2024-09-30
0000790526
rdnt:CapitationArrangementsMember
2025-07-01
2025-09-30
0000790526
rdnt:CapitationArrangementsMember
2024-07-01
2024-09-30
0000790526
rdnt:CapitationArrangementsMember
2025-01-01
2025-09-30
0000790526
rdnt:CapitationArrangementsMember
2024-01-01
2024-09-30
0000790526
2025-07-01
2025-09-30
0000790526
2024-07-01
2024-09-30
0000790526
2024-01-01
2024-09-30
0000790526
us-gaap:CommonStockMember
2025-06-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-30
0000790526
us-gaap:RetainedEarningsMember
2025-06-30
0000790526
us-gaap:ParentMember
2025-06-30
0000790526
us-gaap:NoncontrollingInterestMember
2025-06-30
0000790526
2025-06-30
0000790526
us-gaap:CommonStockMember
2025-07-01
2025-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2025-07-01
2025-09-30
0000790526
us-gaap:ParentMember
2025-07-01
2025-09-30
0000790526
rdnt:EquityIncentivePlanMember
us-gaap:CommonStockMember
2025-07-01
2025-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-07-01
2025-09-30
0000790526
us-gaap:RetainedEarningsMember
2025-07-01
2025-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2025-07-01
2025-09-30
0000790526
us-gaap:CommonStockMember
2025-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2025-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-30
0000790526
us-gaap:RetainedEarningsMember
2025-09-30
0000790526
us-gaap:ParentMember
2025-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2025-09-30
0000790526
us-gaap:CommonStockMember
2024-06-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-30
0000790526
us-gaap:RetainedEarningsMember
2024-06-30
0000790526
us-gaap:ParentMember
2024-06-30
0000790526
us-gaap:NoncontrollingInterestMember
2024-06-30
0000790526
2024-06-30
0000790526
rdnt:EquityIncentivePlanMember
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0000790526
us-gaap:ParentMember
2024-07-01
2024-09-30
0000790526
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2024-07-01
2024-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-07-01
2024-09-30
0000790526
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0000790526
us-gaap:CommonStockMember
2024-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-30
0000790526
us-gaap:RetainedEarningsMember
2024-09-30
0000790526
us-gaap:ParentMember
2024-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2024-09-30
0000790526
2024-09-30
0000790526
us-gaap:CommonStockMember
2024-12-31
0000790526
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0000790526
us-gaap:RetainedEarningsMember
2024-12-31
0000790526
us-gaap:ParentMember
2024-12-31
0000790526
us-gaap:NoncontrollingInterestMember
2024-12-31
0000790526
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-09-30
0000790526
us-gaap:ParentMember
2025-01-01
2025-09-30
0000790526
rdnt:EquityIncentivePlanMember
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0000790526
rdnt:DeepHealthInc.Member
us-gaap:CommonStockMember
2025-01-01
2025-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2025-01-01
2025-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-09-30
0000790526
us-gaap:RetainedEarningsMember
2025-01-01
2025-09-30
0000790526
us-gaap:CommonStockMember
2023-12-31
0000790526
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0000790526
us-gaap:RetainedEarningsMember
2023-12-31
0000790526
us-gaap:ParentMember
2023-12-31
0000790526
us-gaap:NoncontrollingInterestMember
2023-12-31
0000790526
2023-12-31
0000790526
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0000790526
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-30
0000790526
us-gaap:ParentMember
2024-01-01
2024-09-30
0000790526
rdnt:EquityIncentivePlanMember
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0000790526
rdnt:DeepHealthInc.Member
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0000790526
us-gaap:NoncontrollingInterestMember
2024-01-01
2024-09-30
0000790526
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-09-30
0000790526
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-30
0000790526
rdnt:ICADInc.Member
2025-07-17
2025-07-17
0000790526
rdnt:ICADInc.Member
2025-07-17
0000790526
us-gaap:CommercialPaperMember
2025-06-12
0000790526
us-gaap:CommercialPaperMember
2024-04-01
0000790526
rdnt:VenturaCountyImagingGroupLLCMember
2024-03-31
0000790526
rdnt:TriValleyImagingGroupLLCMember
rdnt:TriValleyImagingGroupLLCMember
rdnt:FixedAssetsMember
2024-03-29
0000790526
rdnt:TriValleyImagingGroupLLCMember
rdnt:TriValleyImagingGroupLLCMember
2024-03-29
0000790526
rdnt:StockHoldbackMember
rdnt:HeartLungImagingLimitedMember
2024-03-27
2024-03-27
0000790526
rdnt:StockHoldbackMember
rdnt:HeartLungImagingLimitedMember
2024-03-27
0000790526
us-gaap:UnsecuredDebtMember
2024-01-15
0000790526
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2025-09-30
0000790526
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2024-12-31
0000790526
rdnt:CommercialInsurance1Member
2025-07-01
2025-09-30
0000790526
rdnt:CommercialInsurance1Member
2024-07-01
2024-09-30
0000790526
rdnt:CommercialInsurance1Member
2025-01-01
2025-09-30
0000790526
rdnt:CommercialInsurance1Member
2024-01-01
2024-09-30
0000790526
rdnt:Medicare1Member
2025-07-01
2025-09-30
0000790526
rdnt:Medicare1Member
2024-07-01
2024-09-30
0000790526
rdnt:Medicare1Member
2025-01-01
2025-09-30
0000790526
rdnt:Medicare1Member
2024-01-01
2024-09-30
0000790526
rdnt:Medicaid1Member
2025-07-01
2025-09-30
0000790526
rdnt:Medicaid1Member
2024-07-01
2024-09-30
0000790526
rdnt:Medicaid1Member
2025-01-01
2025-09-30
0000790526
rdnt:Medicaid1Member
2024-01-01
2024-09-30
0000790526
rdnt:WorkersCompensationPersonalInjury1Member
2025-07-01
2025-09-30
0000790526
rdnt:WorkersCompensationPersonalInjury1Member
2024-07-01
2024-09-30
0000790526
rdnt:WorkersCompensationPersonalInjury1Member
2025-01-01
2025-09-30
0000790526
rdnt:WorkersCompensationPersonalInjury1Member
2024-01-01
2024-09-30
0000790526
rdnt:OtherPayorsMember
2025-07-01
2025-09-30
0000790526
rdnt:OtherPayorsMember
2024-07-01
2024-09-30
0000790526
rdnt:OtherPayorsMember
2025-01-01
2025-09-30
0000790526
rdnt:OtherPayorsMember
2024-01-01
2024-09-30
0000790526
rdnt:HealthCareManagementServiceMember
2025-07-01
2025-09-30
0000790526
rdnt:HealthCareManagementServiceMember
2024-07-01
2024-09-30
0000790526
rdnt:HealthCareManagementServiceMember
2025-01-01
2025-09-30
0000790526
rdnt:HealthCareManagementServiceMember
2024-01-01
2024-09-30
0000790526
us-gaap:HealthCareOtherMember
2025-07-01
2025-09-30
0000790526
us-gaap:HealthCareOtherMember
2024-07-01
2024-09-30
0000790526
us-gaap:HealthCareOtherMember
2025-01-01
2025-09-30
0000790526
us-gaap:HealthCareOtherMember
2024-01-01
2024-09-30
0000790526
2023-06-07
0000790526
srt:MinimumMember
rdnt:RestatedPlanMember
2025-01-01
2025-09-30
0000790526
srt:MaximumMember
rdnt:RestatedPlanMember
2025-01-01
2025-09-30
0000790526
srt:MinimumMember
rdnt:ProperyAndEquipmentNetMember
2025-09-30
0000790526
srt:MaximumMember
rdnt:ProperyAndEquipmentNetMember
2025-09-30
0000790526
srt:MinimumMember
us-gaap:LeaseholdImprovementsMember
2025-09-30
0000790526
srt:MaximumMember
us-gaap:LeaseholdImprovementsMember
2025-09-30
0000790526
2024-10-01
2024-10-31
0000790526
rdnt:ImagingCentersMember
2024-12-31
0000790526
rdnt:ArtificialIntelligenceMember
2024-12-31
0000790526
rdnt:ImagingCentersMember
2025-01-01
2025-09-30
0000790526
rdnt:ArtificialIntelligenceMember
2025-01-01
2025-09-30
0000790526
rdnt:ImagingCentersMember
2025-09-30
0000790526
rdnt:ArtificialIntelligenceMember
2025-09-30
0000790526
rdnt:ManagementServiceContractsMember
2025-09-30
0000790526
rdnt:CovenantNotToCompeteMember
2025-09-30
0000790526
us-gaap:CustomerRelationshipsMember
2025-09-30
0000790526
rdnt:PatentAndTrademarksMember
2025-09-30
0000790526
rdnt:DevelopedTechnologySoftwareMember
2025-09-30
0000790526
us-gaap:TradeNamesMember
2025-09-30
0000790526
rdnt:OtherFiniteLivedIntangibleAssetsMember
2025-09-30
0000790526
us-gaap:TradeNamesMember
2025-09-30
0000790526
us-gaap:SoftwareDevelopmentMember
2025-09-30
0000790526
rdnt:ManagementServiceContractsMember
2024-12-31
0000790526
rdnt:CovenantNotToCompeteMember
2024-12-31
0000790526
us-gaap:CustomerRelationshipsMember
2024-12-31
0000790526
rdnt:PatentAndTrademarksMember
2024-12-31
0000790526
rdnt:DevelopedTechnologySoftwareMember
2024-12-31
0000790526
us-gaap:TradeNamesMember
2024-12-31
0000790526
us-gaap:TradeNamesMember
2024-12-31
0000790526
us-gaap:SoftwareDevelopmentMember
2024-12-31
0000790526
us-gaap:LeaseholdImprovementsMember
2025-01-01
2025-09-30
0000790526
rdnt:A2019SWAPSMember
2019-06-30
0000790526
rdnt:October2023Member
rdnt:A2019SWAPSMember
2019-06-30
0000790526
rdnt:October2025Member
rdnt:A2019SWAPSMember
2019-06-30
0000790526
us-gaap:InterestRateSwapMember
rdnt:A2019SWAPSMember
2019-06-30
0000790526
us-gaap:InterestRateSwapMember
rdnt:A2019SWAPS1Member
2019-06-30
0000790526
rdnt:October2023Member
rdnt:A2019SWAPSMember
2023-10-31
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2020-07-01
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2025-06-30
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2025-07-01
2025-09-30
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
2025-07-01
2025-09-30
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2024-12-31
0000790526
us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember
2025-01-01
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
2025-01-01
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:InterestExpenseMember
2025-07-01
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:InterestExpenseMember
2025-01-01
2025-09-30
0000790526
rdnt:HeartAndLungImagingLimitedMember
2025-06-02
0000790526
rdnt:FirstMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-06-02
0000790526
rdnt:FirstMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
rdnt:NewCustomerContractsMember
2025-06-02
0000790526
rdnt:SecondMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-06-02
0000790526
rdnt:ThirdMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-06-02
0000790526
rdnt:ContingentMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-06-02
0000790526
rdnt:FirstMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-09-30
0000790526
rdnt:SecondMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-09-30
0000790526
rdnt:ThirdMilestoneConsiderationMember
rdnt:HeartAndLungImagingLimitedMember
2025-09-30
0000790526
rdnt:KolbRadiologyP.CMember
2025-07-01
0000790526
us-gaap:MonteCarloModelMember
rdnt:KolbRadiologyP.CMember
2025-07-01
0000790526
rdnt:KolbRadiologyP.CMember
rdnt:MeasurementInputRevenueRiskPremiumMember
2025-07-01
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-07-01
0000790526
rdnt:KolbRadiologyP.CMember
rdnt:MeasurementInputOperationalLeverageRatioMember
2025-07-01
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:MeasurementInputCreditSpreadMember
2025-07-01
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-06-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-07-01
2025-09-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-06-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-07-01
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-09-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-06-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-07-01
2025-09-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-06-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-07-01
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-09-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2024-12-31
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-01-01
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2024-12-31
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-01-01
2025-09-30
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2024-12-31
0000790526
us-gaap:AccruedLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-01-01
2025-09-30
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2024-12-31
0000790526
us-gaap:OtherNoncurrentLiabilitiesMember
rdnt:KolbRadiologyP.CMember
2025-01-01
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2025-09-30
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2024-12-31
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2024-12-31
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2024-12-31
0000790526
us-gaap:InterestRateSwapMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2024-12-31
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2025-09-30
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0000790526
rdnt:KolbRadiologyP.CMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2025-09-30
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2025-09-30
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2025-09-30
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2025-09-30
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2025-09-30
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2024-12-31
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2024-12-31
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2024-12-31
0000790526
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2024-12-31
0000790526
us-gaap:RestrictedStockMember
2025-07-01
2025-09-30
0000790526
us-gaap:RestrictedStockMember
2024-07-01
2024-09-30
0000790526
us-gaap:RestrictedStockMember
2025-01-01
2025-09-30
0000790526
us-gaap:RestrictedStockMember
2024-01-01
2024-09-30
0000790526
us-gaap:EmployeeStockOptionMember
2025-07-01
2025-09-30
0000790526
us-gaap:EmployeeStockOptionMember
2024-07-01
2024-09-30
0000790526
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-30
0000790526
us-gaap:EmployeeStockOptionMember
2024-01-01
2024-09-30
0000790526
rdnt:DignityHealthMember
rdnt:JointVentureMember
srt:MinimumMember
rdnt:GlendaleAdvancedImagingMember
2025-01-01
2025-09-30
0000790526
rdnt:DignityHealthMember
rdnt:JointVentureMember
srt:MaximumMember
rdnt:GlendaleAdvancedImagingMember
2025-01-01
2025-09-30
0000790526
us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember
2025-09-30
0000790526
us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember
2024-12-31
0000790526
rdnt:JointVentureInterestMember
2025-09-30
0000790526
rdnt:JointVentureInterestMember
2024-12-31
0000790526
us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember
2025-01-01
2025-09-30
0000790526
us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember
2024-01-01
2024-09-30
0000790526
us-gaap:CommercialPaperMember
2025-07-01
2025-07-01
0000790526
us-gaap:CommercialPaperMember
2025-09-30
0000790526
rdnt:HALOCentersLLCMember
2025-01-02
0000790526
rdnt:HillcroftMedicalClinicMember
2025-03-07
0000790526
rdnt:NorthCountyRadiologyOceansideLLCMember
2025-04-01
0000790526
rdnt:FacultyPhysiciansAndSurgeonsOfLLUSMPalmImagingMember
2025-05-01
0000790526
rdnt:CaliforniaMSKMSOLLCOSSBurbankMember
2025-05-01
0000790526
rdnt:HALOCentersLLCIndianWellsMember
2025-05-01
0000790526
rdnt:KolbRadiologyP.C.Member
2025-07-01
0000790526
rdnt:SchonholzAndDrossmanLLPMember
2025-09-01
0000790526
rdnt:BusinessAcquisitionsMember
2025-09-30
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
2025-06-02
2025-06-02
0000790526
rdnt:CashHoldbackMember
rdnt:SeeModeTechnologiesPteLtdMember
2025-06-02
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
2025-06-02
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:TechnologyBasedIntangibleAssetsMember
2025-06-02
0000790526
rdnt:SeeModeTechnologiesPteLtdMember
us-gaap:InProcessResearchAndDevelopmentMember
2025-06-02
0000790526
2025-07-17
0000790526
rdnt:ICADInc.Member
rdnt:BacklogMember
2025-07-17
2025-07-17
0000790526
rdnt:ICADInc.Member
us-gaap:TradeNamesMember
2025-07-17
2025-07-17
0000790526
rdnt:ICADInc.Member
rdnt:DevelopedTechnologyMember
2025-07-17
2025-07-17
0000790526
rdnt:ICADInc.Member
us-gaap:CustomerRelationshipsMember
2025-07-17
2025-07-17
0000790526
rdnt:PacificDiagnosticImagingGroupLLCMember
rdnt:TriCityHealthcareDistrictMember
2025-04-01
2025-04-01
0000790526
rdnt:PacificDiagnosticImagingGroupLLCMember
2025-04-01
2025-04-01
0000790526
rdnt:ImagingCentersMember
2025-07-01
2025-09-30
0000790526
rdnt:DigitalHealthMember
2025-07-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:ImagingCentersMember
2025-07-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:DigitalHealthMember
2025-07-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:ImagingCentersMember
2025-07-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:DigitalHealthMember
2025-07-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000790526
rdnt:ImagingCentersMember
2024-07-01
2024-09-30
0000790526
rdnt:DigitalHealthMember
2024-07-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:ImagingCentersMember
2024-07-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:DigitalHealthMember
2024-07-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
2024-07-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:ImagingCentersMember
2024-07-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:DigitalHealthMember
2024-07-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
2024-07-01
2024-09-30
0000790526
rdnt:DigitalHealthMember
2025-01-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:ImagingCentersMember
2025-01-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:DigitalHealthMember
2025-01-01
2025-09-30
0000790526
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:ImagingCentersMember
2025-01-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:DigitalHealthMember
2025-01-01
2025-09-30
0000790526
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000790526
rdnt:ImagingCentersMember
2024-01-01
2024-09-30
0000790526
rdnt:DigitalHealthMember
2024-01-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:ImagingCentersMember
2024-01-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
rdnt:DigitalHealthMember
2024-01-01
2024-09-30
0000790526
us-gaap:IntersegmentEliminationMember
2024-01-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:ImagingCentersMember
2024-01-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
rdnt:DigitalHealthMember
2024-01-01
2024-09-30
0000790526
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-30
0000790526
rdnt:BarclaysMember
2025-09-30
0000790526
rdnt:TermLoanMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2024-04-18
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2024-04-18
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2024-04-18
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2024-04-18
2024-04-18
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2024-11-26
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2024-11-26
2024-11-26
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2025-06-11
0000790526
rdnt:BarclaysCreditAgreementMember
rdnt:BarclaysMember
2025-06-11
2025-06-11
0000790526
rdnt:TermLoanMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2025-06-11
2025-06-30
0000790526
rdnt:TermLoanMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2025-01-01
2025-06-10
0000790526
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2023-04-01
2024-04-18
0000790526
us-gaap:BaseRateMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2023-04-01
2024-04-18
0000790526
rdnt:FirstLienTermLoanMember
us-gaap:SecuredDebtMember
2024-04-18
0000790526
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:FirstLienTermLoanMember
us-gaap:SecuredDebtMember
2024-04-18
0000790526
us-gaap:BaseRateMember
rdnt:FirstLienTermLoanMember
us-gaap:SecuredDebtMember
2024-04-18
0000790526
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2024-04-19
2024-11-26
0000790526
us-gaap:RevolvingCreditFacilityMember
us-gaap:PrimeRateMember
rdnt:BarclaysCreditAgreementMember
us-gaap:LineOfCreditMember
2024-04-19
2024-11-26
0000790526
rdnt:BarclaysTermLoanMember
us-gaap:SecuredDebtMember
2024-11-26
0000790526
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:BarclaysTermLoanMember
us-gaap:SecuredDebtMember
2024-11-26
0000790526
us-gaap:PrimeRateMember
rdnt:BarclaysTermLoanMember
us-gaap:SecuredDebtMember
2024-11-26
0000790526
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:BarclaysCreditAgreementMember
us-gaap:SecuredDebtMember
2024-11-27
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
us-gaap:PrimeRateMember
rdnt:BarclaysCreditAgreementMember
us-gaap:LineOfCreditMember
2024-11-27
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysTermLoanMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:OneMonthSecuredOvernightFinancingRateSOFRMember
rdnt:BarclaysTermLoanMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
us-gaap:LineOfCreditMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2024-11-26
2024-11-26
0000790526
us-gaap:RevolvingCreditFacilityMember
us-gaap:PrimeRateMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2024-11-26
2024-11-26
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2025-01-01
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:FirstLienCreditAgreementMember
us-gaap:LineOfCreditMember
2024-12-31
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:FirstLienCreditAgreementMember
us-gaap:LineOfCreditMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:BarclaysMember
rdnt:BarclaysCreditAgreementMember
2024-12-31
0000790526
rdnt:TermLoanMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2022-10-07
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2022-10-07
0000790526
rdnt:TermLoanMember
us-gaap:SecuredOvernightFinancingRateSofrMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2025-01-01
2025-09-30
0000790526
rdnt:TermLoanMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2025-01-01
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2025-01-01
2025-09-30
0000790526
us-gaap:RevolvingCreditFacilityMember
rdnt:TruistMember
rdnt:FirstLienCreditAgreementEighthAmendmentMember
2024-12-31
0000790526
rdnt:FirstLienTermLoanMember
rdnt:TermLoanMember
2025-09-30
0000790526
rdnt:FirstLienTermLoanMember
rdnt:TermLoanMember
2024-12-31
0000790526
rdnt:RestatedAgreementMember
rdnt:TermLoanMember
2025-09-30
0000790526
rdnt:RestatedAgreementMember
rdnt:TermLoanMember
2024-12-31
0000790526
rdnt:EquipmentNotesPayableMember
srt:MinimumMember
2025-09-30
0000790526
rdnt:EquipmentNotesPayableMember
srt:MaximumMember
2025-09-30
0000790526
rdnt:EquipmentNotesPayableMember
2025-09-30
0000790526
rdnt:EquipmentNotesPayableMember
2024-12-31
0000790526
rdnt:RestatedPlanMember
2024-12-31
0000790526
rdnt:RestatedPlanMember
2025-01-01
2025-09-30
0000790526
rdnt:RestatedPlanMember
2025-09-30
0000790526
rdnt:DeepHealthInc.Member
us-gaap:EmployeeStockOptionMember
2020-04-01
2020-06-30
0000790526
rdnt:DeepHealthInc.Member
2020-04-01
2020-06-30
0000790526
rdnt:DeepHealthInc.Member
2025-09-30
0000790526
rdnt:DeepHealthInc.Member
2025-01-01
2025-09-30
0000790526
rdnt:ICADIncOptionTransactionMember
2025-07-01
2025-09-30
0000790526
rdnt:ICADIncOptionTransactionMember
2025-07-17
0000790526
rdnt:ICADIncOptionTransactionMember
2025-07-18
2025-09-30
0000790526
rdnt:ICADIncOptionTransactionMember
2025-09-30
0000790526
rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember
2024-12-31
0000790526
rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember
2025-01-01
2025-09-30
0000790526
rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember
2025-09-30
0000790526
rdnt:PerformanceBasedStockUnitsMember
2024-10-01
2024-10-31
0000790526
srt:MinimumMember
rdnt:PerformanceBasedStockUnitsMember
2024-10-01
2024-10-31
0000790526
srt:MaximumMember
rdnt:PerformanceBasedStockUnitsMember
2024-10-01
2024-10-31
0000790526
rdnt:PerformanceBasedStockUnitsMember
2025-01-01
2025-09-30
0000790526
rdnt:PerformanceBasedStockUnitsMember
2023-01-01
2023-01-31
0000790526
rdnt:PerformanceBasedStockUnitsMember
2023-01-31
0000790526
srt:MinimumMember
rdnt:PerformanceBasedStockUnitsMember
2023-01-01
2023-01-31
0000790526
srt:MaximumMember
rdnt:PerformanceBasedStockUnitsMember
2023-01-01
2023-01-31
0000790526
rdnt:PerformanceBasedStockUnitsMember
2024-03-31
0000790526
rdnt:PerformanceBasedStockOptionsMember
2023-01-01
2023-01-31
0000790526
srt:DirectorMember
rdnt:PerformanceBasedStockOptionsMember
2023-01-31
0000790526
srt:MinimumMember
rdnt:PerformanceBasedStockOptionsMember
2023-01-01
2023-01-31
0000790526
srt:MaximumMember
rdnt:PerformanceBasedStockOptionsMember
2023-01-01
2023-01-31
0000790526
srt:MaximumMember
rdnt:PerformanceBasedStockOptionsMember
2024-03-31
0000790526
rdnt:RemoteDiagnosticImagingPartnersLLCMember
us-gaap:SubsequentEventMember
2025-10-01
2025-10-01
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 
10-Q

(Mark One)
☒
     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended 
September 30, 2025

or
☐
     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 

 to 

Commission File Number 
001-33307

RadNet, Inc.

(Exact name of registrant as specified in its charter)
Delaware
13-3326724
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
1510 Cotner Avenue

Los Angeles,
California
90025
(Address of principal executive offices)
(Zip Code)
(
310
) 
478-7808

(Registrant’s telephone number, including area code)
Not Applicable 
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Class Title
Trading Symbol
Registered Exchange
Common Stock, $0.0001 par value
RDNT
NASDAQ Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
Yes

☒
  No 
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 
Yes

☒
  No 
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes 
☐
 No 
☒
The number of shares of the registrant’s common stock outstanding on November 7, 2025 was 
77,146,342
 shares.
Table of Contents
RADNET, INC.
TABLE OF CONTENTS
Page
PART I – FINANCIAL INFORMATION
1
ITEM 1. Financial Statements
1
Condensed Consolidated Balance Sheets at 
September
 3
0
, 202
5
 and December 31, 20
24
1
Condensed Consolidated Statements of Operations for the 
Three 
and 
Nine

Months
 Ended

Sept
ember
 30
, 202
5
 and 20
24
2
Condensed Consolidated Statements of Comprehensive 
i
ncome 
(loss) 
for the Three 
and 
Nine
 Months 
Ended 
September
 30
, 202
5
 and 20
24
3
Condensed Consolidated Statement of Stockholders' Equity for the Three 
and 
N
ine

Months Ended 
September
 3
0
, 202
5
 and 202
4
4
Condensed Consolidated Statements of Cash Flows for the 
Nine

Months Ended 
September
 30
, 202
5
 and 202
4
7
Notes to Condensed Consolidated Financial Statements
9
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
32
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
50
ITEM 4. Controls and Procedures
51
PART II – OTHER INFORMATION
52
ITEM 1.  Legal Proceedings
52
ITEM 1A.  Risk Factors
52
ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds
52
ITEM 3.  Defaults Upon Senior Securities
52
ITEM 4.  Mine Safety Disclosures
52
ITEM 5.  Other Information
52
ITEM 6.  Exhibits
52
SIGNATURES
53
i
Table of Contents
PART I - FINANCIAL INFORMATION
Item 1 – Financial Statements
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS 
(IN THOUSANDS EXCEPT SHARE DATA)
September 30,
2025
December 31,
2024
(unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents
$
804,716

$
740,020

Accounts receivable
210,548

185,821

Due from affiliates
12,362

41,869

Prepaid expenses and other current assets
50,151

51,542

Total current assets
1,077,777

1,019,252

PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS
Property and equipment, net
780,502

694,791

Operating lease right-of-use assets
675,330

639,740

Total property, equipment and right-of-use assets
1,455,832

1,334,531

OTHER ASSETS
Goodwill
827,532

710,663

Other intangible assets
124,912

81,351

Deferred financing costs
1,829

2,265

Investment in joint ventures
129,127

104,057

Deferred tax assets, net
5,261

—

Deposits and other
43,009

34,571

Total assets
$
3,665,279

$
3,286,690

LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable, accrued expenses and other
$
419,207

$
351,464

Due to affiliates
61,748

43,650

Deferred revenue
8,170

3,288

Current operating lease liability
60,335

56,618

Current portion of notes payable
25,454

24,692

Total current liabilities
574,914

479,712

LONG-TERM LIABILITIES
Long-term operating lease liability
690,935

655,979

Notes payable, net of current portion
1,070,886

991,574

Deferred tax liability, net
—

22,230

Other non-current liabilities
14,585

3,785

Total liabilities
2,351,320

2,153,280

EQUITY
Common stock - $
0.0001
 par value, 
200,000,000
 shares authorized; 
77,032,154
 and 
74,036,993
 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
8

7

Additional paid-in-capital
1,147,402

988,147

Accumulated other comprehensive income (loss)
5,970

(
9,061
)
Accumulated deficit
(
94,840
)
(
76,785
)
Total RadNet, Inc.'s Stockholders' equity:
1,058,540

902,308

Noncontrolling interests
255,419

231,102

Total equity
1,313,959

1,133,410

Total liabilities and equity
$
3,665,279

$
3,286,690

The accompanying notes are an integral part of these financial statements.
1
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
(unaudited)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
REVENUE

Service fee revenue
$
491,426

$
427,579

$
1,398,838

$
1,247,513

Revenue under capitation arrangements
31,443

33,563

93,660

105,050

Total service revenue
522,869

461,142

1,492,498

1,352,563

OPERATING EXPENSES
Cost of operations, excluding depreciation and amortization
450,379

391,800

1,332,944

1,169,113

Lease abandonment charges
2,819

—

8,330

—

Depreciation and amortization
39,799

34,979

111,275

101,822

Loss on sale and disposal of equipment and other
1,042

148

3,168

735

Severance costs
1,441

304

2,614

797

Total operating expenses
495,480

427,231

1,458,331

1,272,467

INCOME FROM OPERATIONS
27,389

33,911

34,167

80,096

OTHER INCOME AND EXPENSES
Interest expense
17,355

19,427

51,783

61,776

Equity in earnings of joint ventures
(
3,567
)
(
3,595
)
(
10,522
)
(
11,308
)
Non-cash change in fair value of interest rate swap
2,371

6,755

6,433

7,429

Debt restructuring and extinguishment expenses
—

147

—

8,909

Other income
(
9,044
)
(
5,414
)
(
24,520
)
(
16,248
)
Total other expenses
7,115

17,320

23,174

50,558

INCOME BEFORE INCOME TAXES
20,274

16,591

10,993

29,538

Provision for income taxes
(
6,385
)
(
4,335
)
(
3,807
)
(
4,927
)
NET INCOME
13,889

12,256

7,186

24,611

Net income attributable to noncontrolling interest
8,472

9,047

25,241

27,163

NET INCOME (LOSS)  ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
5,417

$
3,209

$
(
18,055
)
$
(
2,552
)
BASIC NET INCOME (LOSS)  PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
0.07

$
0.04

$
(
0.24
)
$
(
0.04
)
DILUTED NET INCOME (LOSS)  PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
0.07

$
0.04

$
(
0.24
)
$
(
0.04
)
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic
75,950,350

73,494,709

74,703,658

72,587,321

Diluted
77,388,477

75,165,435

74,703,658

72,587,321

The accompanying notes are an integral part of these financial statements.
2
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) 
(IN THOUSANDS)
(unaudited)

Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
NET INCOME
$
13,889

$
12,256

$
7,186

$
24,611

     Foreign currency translation adjustments
(
874
)
5,228

12,758

2,399

     Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes
217

986

2,273

8,242

COMPREHENSIVE INCOME
13,232

18,470

22,217

35,252

Less comprehensive income attributable to noncontrolling interests
8,472

9,047

25,241

27,163

COMPREHENSIVE INCOME (LOSS)  ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
4,760

$
9,423

$
(
3,024
)
$
8,089

The accompanying notes are an integral part of these financial statements.
3
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
The following table summarizes changes in the Company’s consolidated stockholders' equity, including noncontrolling interest, during the three months ended September 30, 2025 and September 30, 2024.
Common Stock
Shares
Amount
Additional Paid-In Capital
Accumulated Other Comprehensive income (loss)
Accumulated Deficit
Total RadNet, Inc.'s Equity
Noncontrolling Interests
Total Equity
BALANCE - JUNE 30, 2025
75,067,102

$
8

$
1,025,936

$
6,627

$
(
100,257
)
$
932,314

$
246,947

$
1,179,261

Issuance of common stock upon exercise of options
49,080

— 
1,704

— 
— 
1,704

— 
1,704

Issuance of common stock under the equity compensation plan
68,599

— 
— 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
9,191

— 
— 
9,191

— 
9,191

Forfeiture of restricted stock and share cancellation
(
779
)
— 
(
150
)
— 
— 
(
150
)
— 
(
150
)
Issuance of common stock in connection with acquisitions
1,848,152

— 
110,721

— 
— 
110,721

— 
110,721

Change in cumulative foreign currency translation adjustment
— 
— 
— 
(
874
)
— 
(
874
)
— 
(
874
)
Change in fair value of cash flow hedge from prior periods reclassified to earnings
— 
— 
— 
217

— 
217

— 
217

Net income
— 
— 
— 
— 
5,417

5,417

8,472

13,889

BALANCE - SEPTEMBER 30, 2025
77,032,154

$
8

$
1,147,402

$
5,970

$
(
94,840
)
$
1,058,540

$
255,419

$
1,313,959

BALANCE - JUNE 30, 2024
73,968,042

$
7

$
974,355

$
(
8,057
)
$
(
85,339
)
$
880,966

$
211,874

$
1,092,840

Issuance of common stock under the equity compensation plan
9,075

— 
— 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
4,727

— 
— 
4,727

— 
4,727

Forfeiture of restricted stock and share cancellation
(
833
)
— 
(
4
)
— 
— 
(
4
)
— 
(
4
)
Contribution from noncontrolling partner
— 
— 
201

— 
— 
201

— 
201

Sale of economic interests in majority owned subsidiary, net of taxes
— 
— 
— 
— 
— 
— 
3,400

3,400

Change in cumulative foreign currency translation adjustment
— 
— 
— 
5,228

— 
5,228

— 
5,228

Change in fair value of cash flow hedge from prior periods reclassified to earnings
— 
— 
— 
986

— 
986

— 
986

Net income
— 
— 
— 
— 
3,209

3,209

9,047

12,256

BALANCE - SEPTEMBER 30, 2024
73,976,284

$
7

$
979,279

$
(
1,843
)
$
(
82,130
)
$
895,313

$
224,321

$
1,119,634

 The accompanying notes are an integral part of these financial statements.
4
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
The following table summarizes changes in the Company’s consolidated stockholders' equity, including noncontrolling interest, during the nine months ended September 30, 2025 and September 30, 2024.
5
Table of Contents
6
Table of Contents
Common Stock
Shares
Amount
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total RadNet, Inc.'s Equity
Noncontrolling Interests
Total Equity
BALANCE - DECEMBER 31, 2024
74,036,993

$
7

$
988,147

$
(
9,061
)
$
(
76,785
)
$
902,308

$
231,102

$
1,133,410

Issuance of common stock upon exercise of options
111,376

1

2,258

— 
— 
2,259

— 
2,259

Issuance of common stock under the equity compensation plan
1,039,311

— 
— 
— 
— 
— 
— 
— 
Issuance of common stock under the DeepHealth equity compensation plan
3,438

— 
— 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
46,466

— 
— 
46,466

— 
46,466

Issuance of common stock in connection with acquisitions
1,848,152

— 
110,721

— 
— 
110,721

— 
110,721

Forfeiture of restricted stock and share cancellation
(
7,116
)
— 
(
190
)
— 
— 
(
190
)
— 
(
190
)
Distributions paid to noncontrolling interests
— 
— 
— 
— 
— 
— 
(
3,313
)
(
3,313
)
Contributions from noncontrolling interests
— 
— 
— 
— 
— 
— 
2,389

2,389

Change in cumulative foreign currency translation adjustment
— 
— 
— 
12,758

— 
12,758

— 
12,758

Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes
— 
— 
— 
2,273

— 
2,273

— 
2,273

Net (loss) income
— 
— 
— 
— 
(
18,055
)
(
18,055
)
25,241

7,186

BALANCE - SEPTEMBER 30, 2025
77,032,154

$
8

$
1,147,402

$
5,970

$
(
94,840
)
$
1,058,540

$
255,419

$
1,313,959

BALANCE - DECEMBER 31, 2023
67,956,318

$
7

$
722,750

$
(
12,484
)
$
(
79,578
)
$
630,695

$
182,664

$
813,359

Issuance of common stock upon exercise of options
60,605

— 
367

— 
— 
367

— 
367

Issuance of common stock under the equity compensation plan
666,962

— 
— 
— 
— 
— 
— 
— 
Issuance of common stock under the DeepHealth equity compensation plan
9,377

— 
— 
— 
— 
— 
— 
— 
Stock-based compensation expense
— 
— 
21,406

— 
— 
21,406

— 
21,406

Sale of economic interests in majority owned subsidiary, net of taxes
— 
— 
— 
— 
— 
— 
16,917

16,917

Issuance of common stock
5,232,500

—

218,385

— 
— 
218,385

— 
218,385

Issuance of common stock in connection with acquisitions
95,019

— 
4,607

— 
— 
4,607

— 
4,607

Forfeiture of restricted stock and share cancellation
(
44,497
)
— 
(
38
)
— 
— 
(
38
)
— 
(
38
)
Distributions paid to noncontrolling interests
— 
— 
— 
— 
— 
— 
(
2,423
)
(
2,423
)
Contributions from noncontrolling interests
— 
— 
11,802

— 
— 
11,802

— 
11,802

Change in cumulative foreign currency translation adjustment
— 
— 
— 
2,399

— 
2,399

— 
2,399

Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes
— 
— 
— 
8,242

— 
8,242

— 
8,242

Net (loss) income
— 
— 
— 
— 
(
2,552
)
(
2,552
)
27,163

24,611

BALANCE - SEPTEMBER 30, 2024
73,976,284

$
7

$
979,279

$
(
1,843
)
$
(
82,130
)
$
895,313

$
224,321

$
1,119,634

     The accompanying notes are an integral part of these financial statements.
7
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)

Nine Months Ended September 30,
2025
2024
CASH FLOWS FROM OPERATING ACTIVITIES

Net income
$
7,186

$
24,611

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
111,275

101,822

Noncash operating lease expense
44,605

45,516

Equity in earnings of joint ventures, net of dividends
(
4,590
)
(
10,308
)
Amortization of deferred financing costs and loan discount
2,242

2,336

Loss on sale and disposal of equipment
3,168

735

Loss on extinguishment of debt
—

2,080

Lease abandonment charges
8,330

—

Amortization of cash flow hedge
2,273

8,242

Non-cash change in fair value of interest rate swap
6,433

7,429

Stock-based compensation
46,276

21,368

Loss on impairment
—

1,200

Change in fair value of contingent consideration
—

1,974

Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable
(
20,476
)
(
35,369
)
Other current assets
2,093

4,738

Other assets
(
2,764
)
(
7,388
)
Deferred taxes
2

4,834

Operating leases
(
48,760
)
(
40,497
)
Deferred revenue
3,934

(
255
)
Accounts payable, accrued expenses and other
53,429

57,426

Net cash provided by operating activities
214,656

190,494

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities and other acquisitions, net of cash acquired
(
66,464
)
(
37,748
)
Purchase of property and equipment and other
(
162,221
)
(
145,164
)
Proceeds from sale of equipment
75

151

Equity contributions in existing and purchase of interest in joint ventures
(
4,147
)
(
1,496
)
Collection of notes receivable
2,832

—

Net cash used in investing activities
(
229,925
)
(
184,257
)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable
(
5,229
)
(
4,296
)
Payments on Term Loan Debt
(
15,504
)
(
688,375
)
Proceeds from issuance of new debt, net of issuing costs
99,001

863,815

Purchase of noncontrolling interests by third party
2,389

7,569

Payments on contingent consideration and holdbacks
—

(
3,614
)
Distributions paid to noncontrolling interests
(
3,313
)
(
2,423
)
Proceeds from sale of economic interests in majority owned subsidiary, net of taxes
—

8,641

Proceeds from issuance of common stock
—

218,385

Proceeds from issuance of common stock upon exercise of options
2,258

367

Net cash provided by financing activities
79,602

400,069

EFFECT OF EXCHANGE RATE CHANGES ON CASH
363

40

NET INCREASE IN CASH AND CASH EQUIVALENTS
64,696

406,346

CASH AND CASH EQUIVALENTS, beginning of period
740,020

342,570

CASH AND CASH EQUIVALENTS, end of period
$
804,716

$
748,916

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest
$
53,679

$
57,227

Cash paid during the period for income taxes
$
3,480

$
2,202

The accompanying notes are an integral part of these financial statements.
8
Table of Contents
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(unaudited)
Supplemental Schedule of Non-Cash Investing and Financing Activities
We acquired equipment and certain leasehold improvements for approximately $
81.8
 million and $
43.2
 million during the nine months ended September 30, 2025 and 2024, respectively, which were not paid for as of September 30, 2025 and 2024
,
 respectively. The amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.
During the nine months ended September 30, 2025, we acquired certain assets from entities engaged in the practice of radiology or related businesses. These acquisitions included holdbacks, contingent liabilities and other liabilities totaling $
21.0
 million that we had not paid for as of September 30, 2025. The accrued amounts are reflected in our condensed consolidated balance sheets under accrued expenses and other non-current liabilities.
During the nine months ended September 30, 2025, we made a deemed contribution to a joint venture of approximately $
16.3
 million, which resulted in a corresponding decrease in due from affiliates.
On July 17, 2025, we issued 
1,848,152
 of common stock to complete our purchase of iCAD, Inc. The shares were ascribed a value of $
105.8
 million.
On June 12, 2025, we entered into a $
17.0
 million promissory note with Dignity Health, a related party and joint venture member of Arizona Diagnostic Radiology Group, LLC, to reclassify a previously outstanding balance from due from affiliates to prepaid expenses and other current assets. As a result, a non-cash reclassification of $
5.7
 million was made from Other Current Assets to Other Assets to reflect the long-term portion of the note.
On April 1, 2024, we issued promissory notes in the amount of $
6.3
 million to acquire radiology equipment previously leased under operating leases.
On March 31, 2024, we issued an additional 
12.5
% in noncontrolling interest in our Ventura County Imaging Group, LLC joint venture in exchange for $
5.1
 million which was not paid for as of March 31, 2024. The amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.
On March 29, 2024, we received $
1.4
 million in fixed assets, imaging equipment, and $
6.0
 million in goodwill from our partner in Tri Valley Imaging Group, LLC. See Note 4, Business combinations and related activity contained herein.
On March 27, 2024, we issued 
95,019
 shares of common stock to settle the stock contingent liabilities as part of our purchase of Heart & Lung Imaging Limited. The shares were ascribed a value of $
4.6
 million.
On January 15, 2024, we issued promissory notes in the amount of $
6.9
 million to acquire radiology equipment previously leased under operating leases.
9
Table of Contents
RADNET, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1 – 
NATURE OF BUSINESS AND BASIS OF PRESENTATION
We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At September 30, 2025, we operated directly or indirectly through joint ventures with hospitals, 
407
 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. 
The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation.   All of these affiliated entities are referred to collectively as “RadNet,” “we,” “us,” “our” or the “Company” in this report.
Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.
VIEs that we consolidate as the primary beneficiary include professional corporations which are owned or controlled by individuals within our senior management and provide professional medical services for centers in Arizona, California, Delaware, Maryland, New Jersey and New York. These VIEs are collectively referred to as the “Consolidated Medical Group".  RadNet provides non-medical, technical and administrative services to the Consolidated Medical Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Consolidated Medical Group has insignificant operating assets and liabilities, and de minimis equity.  Substantially all cash flows of the Consolidated Medical Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Consolidated Medical Group.  The creditors of the Consolidated Medical Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of the Consolidated Medical Group. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.
The Consolidated Medical Group on a combined basis recognized $
67.8
 million and $
55.3
 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2025 and 2024, respectively and $
67.8
 million and $
55.3
 million of operating expenses for the three months ended September 30, 2025 and 2024, respectively.  RadNet recognized $
236.7
 million and $
207.4
 million of total billed net service fee revenue for the three months ended September 30, 2025, and 2024, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.
The Consolidated Medical Group on a combined basis recognized $
191.6
 million and $
162.5
 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2025 and 2024, respectively and $
191.6
 million and $
162.5
 million of operating expenses for the nine months ended September 30, 2025 and 2024, respectively.  RadNet recognized $
687.1
 million and $
673.3
 million of total billed net service fee revenue for the nine months ended September 30, 2025, and 2024, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.
In our condensed consolidated balance sheets at September 30, 2025 and December 31, 2024, we have included approximately $
131.9
 million and $
103.0
 million, respectively, of accounts receivable and approximately $
32.0
 million and $
22.7
 million of accounts payable and accrued liabilities related to the Consolidated Medical Group, respectively. The cash 
10
Table of Contents
flows of the Consolidated Medical Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation.
At all of our centers not serviced by the Consolidated Medical Group we have entered into long-term contracts with medical groups to provide professional services at those centers, including supervision and interpretation of diagnostic imaging procedures. The medical groups maintain full control over the physicians they employ. Through our management agreements, we make available to the medical groups the imaging centers, including all furniture, fixtures and medical equipment therein.  The medical groups are compensated for their services from the professional component of the global net service fee revenue and after deducting management service fees paid to us, we have no economic controlling interest in these medical groups. As such, the financial results of these groups are not consolidated in our financial statements.
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended September 30, 2025 and 2024 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2024.
NOTE 2 - 
SIGNIFICANT ACCOUNTING POLICIES
There have been no material changes to the significant accounting policies we use and have explained in our annual report on Form 10-K for the fiscal year ended December 31, 2024. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2024.
REVENUE  - Our revenue generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenue are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our service fee revenue is based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenue related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenue at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.
11
Table of Contents
Our total revenues for the three and nine months ended September 30, 2025 and 2024 are presented in the table below. Our patient service revenue is displayed as the estimated service fee, broken down by classification of insurance coverage type, along with revenue generated from our management services and other sources such as software and AI.
In Thousands
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Commercial insurance
$
287,769

$
255,376

$
829,295

$
752,515

Medicare
123,254

102,853

347,641

298,001

Medicaid
13,470

10,894

37,735

32,804

Workers' compensation/personal injury
11,347

10,233

32,460

33,088

Other payors
29,962

25,366

87,064

77,336

Management fee revenue
7,044

6,241

20,011

18,255

Other revenue
18,580

16,616

44,632

35,514

Revenue under capitation arrangements
31,443

33,563

93,660

105,050

Total service revenue
$
522,869

$
461,142

$
1,492,498

$
1,352,563

EQUITY BASED COMPENSATION – We have 
one
 long-term incentive plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approval by our stockholders at our annual stockholders meeting on June 7, 2023 (the “Restated Plan”). We have reserved 
20,100,000
 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights.  Terms and conditions of awards can be direct grants or based on achieving a performance metric. We evaluate performance-based awards to determine if it is probable that the vesting conditions will be met. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period.  Stock options generally vest over 
three years
 to 
five years
 and expire 
five years
 to 
ten years
 from date of grant.  We determine the compensation expense for each stock option award using the Black Scholes, binomial lattice valuation or similar, valuation model.  Those models require that our management make certain estimates concerning risk-free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees.  
In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock.  No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan.  
In connection with our acquisition of iCAD, Inc. on July 17, 2025, we assumed the iCAD, Inc. 2016 Stock Incentive Plan, as amended, and the iCAD, Inc. 2012 Stock Incentive Plan, as amended by Amendment No. 1 (collectively, the “iCAD Plans”), including outstanding option awards that became exercisable for shares of our common stock. No additional awards will be granted under the iCAD Plans.
See Note 7, Stock-Based Compensation, for more information.
ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.
We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long-term portion.  Amounts remaining to be collected on these agreements were $
4.1
 million and $
4.2
 million at September 30, 2025 and December 31, 2024, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.
12
Table of Contents
DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities.
 Deferred financing costs, net of accumulated amortization, were $
1.8
 million and $
2.3
 million as of September 30, 2025 and December 31, 2024, respectively.  See Note 6, Credit Facilities and Notes Payable for more information.
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 
3
 to 
15
 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 
3
 to 
15
 years. Maintenance and repairs are charged to expense as incurred.
BUSINESS COMBINATIONS  -  When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
Acquisition-related costs are expensed as incurred and are included in Cost of operations, excluding depreciation and amortization, in the condensed consolidated statements of operations.
 For the three and nine ended September 30, 2025, such costs totaled approximately $
2.1
 million and $
5.1
 million, respectively. For the three and nine ended September 30, 2024, such costs totaled approximately $
0.4
 million.
GOODWILL
 - Goodwill at September 30, 2025 totaled $
827.5
 million. 
Goodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit.  We tested goodwill and indefinite lived intangibles for impairment on October 1, 2024 noting 
no
 impairment, and we have not identified any indicators of impairment through September 30, 2025.

Activity in goodwill for the nine months ended September 30, 2025 is provided below (in thousands):
Imaging Center segment
Digital Health segment
Total
Balance as of December 31, 2024
628,537

$
82,126

$
710,663

Goodwill from acquisitions
61,306

47,084

108,391

Measurement period and other adjustments
—

87

87

Currency translation
1,741

6,650

8,391

Balance as of September 30, 2025
$
691,584

$
135,948

$
827,532

The amount of goodwill that is expected to be deductible for tax purposes as of September 30, 2025 is $
137.6
 million.
INTANGIBLE ASSETS - Intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. 
The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2025 and December 31, 2024 are as follows (in thousands):
As of September 30, 2025:
13
Table of Contents
2025*
2026
2027
2028
2029
Thereafter
Total
Weighted average amortization period remaining in years
Management service contracts
$
572

$
2,287

$
2,287

$
2,287

$
2,287

$
4,384

$
14,104

6.2
Covenant not to compete and other contracts
258

787

493

403

234

45

2,220

3.2
Customer lists
757

2,960

2,782

2,740

2,740

30,648

42,627

15.4
Patent and trademarks
278

763

391

326

67

127

1,952

3.2
Developed technology
2,438

9,714

9,180

9,180

3,952

8,982

43,446

5.2
Trade names amortized
35

138

138

103

19

8

441

3.3
Others
109

438

438

438

219

— 
1,642

3.8
Trade names indefinite life
— 
— 
— 
— 
— 
8,500

8,500

IPR&D
— 
— 
— 
— 
— 
9,980

9,980

Total annual amortization
$
4,447

$
17,087

$
15,709

$
15,477

$
9,518

$
62,674

$
124,912

*Excluding the nine months ended September 30, 2025
As of December 31, 2024: 
2025
2026
2027
2028
2029
Thereafter
Total
Weighted average amortization period remaining in years
Management service contracts
$
2,287

$
2,287

$
2,287

$
2,287

$
2,291

$
4,384

$
15,823

6.9
Covenant not to compete and other contracts
947

660

365

275

106

—

2,353

3.2
Customer lists
1,084

962

786

750

750

9,628

13,960

17.2
Patent and trademarks
293

293

293

293

51

121

1,344

5.0
Developed technology
7,329

7,289

6,755

6,755

1,848

4,610

34,586

5.4
Trade names amortized
77

77

77

63

19

8

321

4.3
Trade names indefinite life
— 
— 
— 
— 
— 
8,500

8,500

IPR&D
— 
— 
— 
— 
— 
4,464

4,464

Total annual amortization
$
12,017

$
11,568

$
10,563

$
10,423

$
5,065

$
31,715

$
81,351

Total intangible asset amortization expense was $
4.5
 million and $
10.8
 million for the three and nine months ended September 30, 2025, respectively. Total amortization expense was $
3.1
 million and $
9.4
 million for the three and nine months ended September 30, 2024, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management services agreements are amortized over 
25
 years using the straight-line method. Developed technology is capitalized and amortized over the useful life of the software when placed into service. Trade names and IPR&D are reviewed annually for impairment, or when indicators of impairment are presented.
INCOME TAXES -  Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets, we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.
On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law, which enacts significant changes to the U.S. Tax and related laws. Some of the provisions of the new tax law that affect corporations include, but are not limited to, reinstatement of immediate expensing of domestic specified research or experimental expenditures, restoration of EBITDA as the base for calculating deductible business interest expense, modifications to international tax regimes, and reenactment of one hundred percent bonus depreciation on eligible property acquired after January 19, 2025. The Company has evaluated the impact that the new tax law will have on its financial condition and results of operations. The impact of the tax law changes from the OBBBA has been reflected in the Company’s financial statements for the nine months ended September 30, 2025, and has been applied prospectively based on the effective dates of the tax law. The enactment of the OBBBA did not have a material impact on the Company’s financial statements.
14
Table of Contents
In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to support certain components of Pillar Two Model Rules beginning 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. The model rules provide a framework for applying the minimum tax, countries may enact Pillar Two Model Rules slightly differently than the model rules and on different timelines and may adjust domestic tax incentives in response to Pillar Two Model Rules. On a long-term basis, we will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in all countries applicable to us. For 2025, we expect that we will meet one or more transactional safe harbor rules, and as such, we do not believe Pillar Two model will have an impact on our annual effective tax rate for the year ending December 31, 2025.
We recorded an income tax provision of $
6.4
 million, or an effective tax rate of 
31.5
%, for the three months ended September 30, 2025, compared to $
4.3
 million, or an effective tax rate of 
26.1
% for the three months ended September 30, 2024.  We recorded an income tax provision of $
3.8
 million, or an effective tax rate of 
34.6
%, for the nine months ended September 30, 2025 compared to an income tax provision of $
4.9
 million, or an effective tax rate of 
16.7
% for the nine months ended September 30, 2024. The income tax rates for the three and nine months ended September 30, 2025 diverge from the federal statutory rate due to (i) officer's compensation limitations; (ii) nondeductible stock compensation expense; (iii) partial valuation allowance on losses in foreign jurisdictions, partially offset by (iv) noncontrolling interests from controlled partnerships
LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable.  We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.  For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component. 
ROU assets are
 tested for impairment if circumstances suggest that the carrying amount may not be recoverable.  Our ROU assets consist of facility and equipment assets on operating leases.  No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of September 30, 2025.  Our facility leases require us to maintain insurance policies which would cover major damage to our facilities.  We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances.  Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.
We closely monitor patient levels at our imaging centers and occasionally divest or shut down centers to maximize utilization rates. We may abandon low utilization leases and divert the patients to nearby centers. During the nine months ended September 30, 2025, we closed several imaging centers with lower utilization and recognized lease abandonment charges of approximately $
8.3
 million in our Imaging Center segment. Of these amounts, $
6.5
 million were related to right-of-use assets impairment and $
1.9
 million were related to the write-off of leasehold improvements for the nine months ended September 30, 2025.
COMPREHENSIVE INCOME (LOSS)  - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) ("OCI") and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in OCI. The components of OCI for the three and nine months ended September 30, 2025 and 2024 are included in the Condensed Consolidated Statements of Comprehensive Income.

The following is a reconciliation of Foreign Currency Translation amounts for the three and nine months ended September 30, 2025 and 2024 is provided below (in thousands):
For the three months ended September 30, 2025
June 30, 2025 Balance
Currency Translation Adjustments Balance
September 30, 2025 Balance
Currency Translation Adjustments
$
7,935
$(
874
)
$
7,061
15
Table of Contents
For the nine months ended September 30, 2025
December 31, 2024 Balance
Currency Translation Adjustments Balance
September 30, 2025 Balance
Currency Translation Adjustments
$(
5,697
)
$
12,758
$
7,061
INTEREST ON SECURITIES - We recognized income from interest on securities of approximately $
8.9
 million and $
9.6
 million for the three months ended September 30, 2025 and 2024, respectively, and $
24.4
 million and $
22.7
 million for the nine months ended September 30, 2025 and 2024. This income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations
.
COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.
DERIVATIVE INSTRUMENTS
 - In the second quarter of 2019, we entered into 
four
 forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $
500.0
 million, consisting of 
two
 agreements of $
50.0
 million each and 
two
 agreements of $
200.0
 million each.  
The 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional.
 Under these arrangements, we arranged the 2019 Swaps with locked in 1 month Term Secured Overnight Financing Rate ("SOFR") rates at 
1.89
% for the $
100.0
 million notional and at 
1.98
% for the $
400.0
 million notional.  In October of 2023, the 
two
 agreements of $
50,000,000
 each matured. 
As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates.
At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of other accumulated comprehensive loss in the consolidated statement of equity.
  The remaining gain or loss, if any, is recognized in earnings. Effective July 1, 2020, it was determined that hedge accounting no longer applied and accordingly after that date all changes in the fair value of the swaps is recognized in earnings. The amount included in accumulated other comprehensive income as of that date was approximately $
24.4
 million, net of taxes.
A tabular presentation of the effect of derivative instruments on our condensed consolidated statement of comprehensive income of the 2019 Swaps is as follows (amounts in thousands):
For the three months ended September 30, 2025
Account
June 30, 2025 Balance
Amount of comprehensive loss recognized on derivative net of taxes
Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*
September 30, 2025 Balance
Location
Accumulated Other Comprehensive Loss, net of taxes
$(
217
)
$
—
$
217
$
—
Equity
*Net of taxes of  $
0
 for the three months ended September 30, 2025.
16
Table of Contents
For the nine months ended September 30, 2025
Account
December 31, 2024 Balance
Amount of comprehensive loss recognized on derivative net of taxes
Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*
September 30, 2025 Balance
Location
Accumulated Other Comprehensive Loss, net of taxes
$(
2,273
)
$
—
$
2,273
$
—
Equity
*Net of taxes of  $
0.7
 million for the nine months ended September 30, 2025.
A tabular presentation of the effect of the 2019 Swaps on our statement of operations is as follows (amounts in thousands):
For the three months ended September 30, 2025
Ineffective interest rate swap
Amount recognized (current period ineffective portion)
Location recognized in profit and loss (current period ineffective portion)
Amount reclassified from accumulated OCI (prior period effective portion)
Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts
$
2,371

Other income (expense)
$
217

Interest Expense
For the nine months ended September 30, 2025
Ineffective interest rate swap
Amount recognized (current period ineffective portion)
Location recognized in profit and loss (current period ineffective portion)
Amount reclassified from accumulated OCI (prior period effective portion)
Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts
$
6,433

Other income (expense)
$
2,273

Interest Expense
See Fair Value Measurements below for the fair value of the 2019 Swaps at September 30, 2025.
CONTINGENT CONSIDERATION -
See-Mode Technologies Pte. Ltd.
On June 2, 2025, we completed our acquisition of all the equity interests of See-Mode Technologies Pte. Ltd., a Singapore-based AI company specializing in medical imaging. As part of the purchase agreement, we agreed to pay up to $
12.7
 million in contingent consideration in RadNet common stock and cash, based on the achievement of three clinical and regulatory milestones:
First Milestone ($
4.3
 million): Payable upon successful implementation of the company’s thyroid ultrasound detection product at 
four
 RadNet imaging centers, and execution of at least 
two
 new customer contracts totaling $
150,000
 in aggregate annual contract value by March 31, 2026.
Second Milestone ($
4.2
 million): Payable upon FDA 510(k) clearance of the company’s breast ultrasound detection product, with submission required by March 31, 2026 and approval by December 31, 2026.
17
Table of Contents
Third Milestone ($
4.2
 million): Payable upon FDA 510(k) clearance of a new ultrasound product, with submission required by June 30, 2027 and approval by March 31, 2028.
Each contingent amount is payable 
50
% in cash and 
50
% in RadNet common shares. As of September 30, 2025, the fair value of the contingent consideration will be assessed quarterly based on the probability of milestone achievement, which as of the acquisition date was determined by management to be 
97.5
%, 
70
% and 
40
% for the First, Second and Third Milestone, respectively. As of September 30, 2025, those percentages remain unchanged.
Kolb Radiology P.C.
On July 1, 2025, we completed the acquisition of substantially all the assets of Kolb Radiology P.C., a New York-based diagnostic imaging practice.  As part of the purchase agreement, we agreed to pay up to $
8.0
 million in contingent consideration (“Earnout Consideration”) payable based on the financial performance of the acquired business over three consecutive twelve-month periods following the closing date.
The fair value of the contingent consideration was estimated at $
4.5
 million at the acquisition date using a Monte Carlo simulation under a risk-neutral framework that modeled projected MRI revenues and discounted expected payments at term-matched U.S. Treasury rates plus RadNet’s credit spread. Key assumptions included a 
2.5
% revenue risk premium, 
15
% revenue volatility, 
50
% operational leverage ratio, and 
2.3
% credit spread.
A tabular roll forward of contingent consideration is as follows (amounts in thousands):
For the three months ended September 30, 2025
Entity
Account
June 30, 2025 Balance
Additions
Settlement of contingent consideration
Change in valuation of contingent consideration
September 30, 2025 Balance
See-Mode Technologies Pte. Ltd.
Accrued expenses 
$
2,114

$
—

$
—

$
—

$
2,114

See-Mode Technologies Pte. Ltd.
Other non-current liabilities
$
6,652

$
—

$
—

$
—

$
6,652

Kolb Radiology P.C.
Accrued expenses
—

$
3,100

$
—

$
—

$
3,100

Kolb Radiology P.C.
Other non-current liabilities
—

$
1,400

$
—

$
—

$
1,400

For the nine months ended September 30, 2025
Entity
Account
January 1, 2025 Balance
Additions
Settlement of contingent consideration
Change in valuation of contingent consideration
September 30, 2025 Balance
See-Mode Technologies Pte. Ltd.
Accrued expenses 
—

$
2,114

$
—

$
—

$
2,114

See-Mode Technologies Pte. Ltd.
Other non-current liabilities
—

$
6,652

$
—

$
—

$
6,652

Kolb Radiology P.C.
Accrued expenses
—

$
3,100

$
—

$
—

$
3,100

Kolb Radiology P.C.
Other non-current liabilities
—

$
1,400

$
—

$
—

$
1,400

18
Table of Contents
FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.
Derivatives:
The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):

As of September 30, 2025
Level 1
Level 2
Level 3
Total
Current assets

2019 Swaps - Interest Rate Contracts
$
—

$
679

$
—

$
679

As of December 31, 2024
Level 1
Level 2
Level 3
Total
Current assets

2019 Swaps - Interest Rate Contracts
$
—

$
7,112

$
—

$
7,112

The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward SOFR curve. The forward SOFR curve is readily available in the public markets or can be derived from information available in the public markets.
Contingent Consideration:
The table below summarizes the estimated fair values of contingent consideration relating to our acquisition that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):

As of September 30, 2025
Level 1
Level 2
Level 3
Total
Accrued expenses and other non-current liabilities

See-Mode Technologies
$
—

$
—

$
8,766

$
8,766

Kolb Radiology P.C.
$
—

$
—

$
4,500

$
4,500

Long Term Debt:
The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands):

As of September 30, 2025
Level 1
Level 2
Level 3
Total Fair Value
Total Face Value
Barclays Term Loan and Truist Term Loan
$
—

$
1,090,121

$
—

$
1,090,121

$
1,090,121

19
Table of Contents

As of December 31, 2024
Level 1
Level 2
Level 3
Total Fair Value
Total Face Value
Barclays Term Loan and Truist Term Loan
$
—

$
1,006,713

$
—

$
1,006,713

$
1,005,625

The estimated fair value of our long-term debt, which is discussed in Note 6, Credit Facilities and Notes Payable, was determined using Level 2 inputs primarily related to comparable market prices.
We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our other notes payable to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.
EARNINGS PER SHARE - 
Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
NET INCOME (LOSS)  ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
$
5,417

$
3,209

$
(
18,055
)
$
(
2,552
)
BASIC NET INCOME (LOSS)  PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period
75,950,350

73,494,709

74,703,658

72,587,321

Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders
$
0.07

$
0.04

$
(
0.24
)
$
(
0.04
)
DILUTED NET INCOME (LOSS)  PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period
75,950,350

73,494,709

74,703,658

72,587,321

Add non-vested restricted stock subject only to service vesting
241,221

233,235

—

—

Add additional shares issuable upon exercise of stock options and contingently issuable shares
1,196,906

1,437,491

—

—

Weighted average number of common shares used in calculating diluted net income per share
77,388,477

75,165,435

74,703,658

72,587,321

Net income (loss) attributable to RadNet, Inc's common stockholders for diluted share calculation
$
5,417

$
3,209

$
(
18,055
)
$
(
2,552
)
Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders
$
0.07

$
0.04

$
(
0.24
)
$
(
0.04
)
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Non-vested restricted stock subject to service vesting
—

—

929,203

685,104

Shares issuable upon the exercise of stock options
—

—

860,442

831,647

INVESTMENTS IN EQUITY SECURITIES–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance 
20
Table of Contents
allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.

As of September 30, 2025, we have 
four
 equity investments with an aggregate carrying value of $
9.3
 million.  
No other observable price changes or impairments in our investments were identified as of September 30, 2025. 
INVESTMENT IN JOINT VENTURES – We have 
12
 unconsolidated joint ventures with ownership interests ranging from 
35
% to 
55
%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2025.
Joint venture investment and financial information
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2025 (in thousands):
Balance as of December 31, 2024
$
104,057

Equity in earnings in joint ventures
10,522

Distribution of earnings
(
5,932
)
Equity contributions in existing joint ventures
20,480

Balance as of September 30, 2025
$
129,127

We charged management service fees from the centers underlying these joint ventures of approximately $
6.5
 million and $
5.9
 million for the three months ended September 30, 2025 and 2024 and $
19.1
 million and $
17.8
 million for the nine months ended September 30, 2025 and 2024, respectively. These joint ventures are considered related parties. Amounts transacted between us and the entities are in the ordinary course of business and are disclosed on our balance sheet in the due from/to affiliate accounts.
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2025 and December 31, 2024 and income statement data for the nine months ended September 30, 2025 and 2024 (in thousands):
Balance Sheet Data:
September 30, 2025
December 31, 2024
Current assets
$
73,433

$
61,158

Noncurrent assets
230,879

232,750

Current liabilities
(
9,972
)
(
53,182
)
Noncurrent liabilities
(
72,316
)
(
70,241
)
Total net assets
$
222,023

$
170,485

Income statement data for the nine months ended September 30,
2025
2024
Net revenue
$
211,003

$
195,905

Net income
$
22,628

$
23,949

Promissory Note from Joint Venture Member
On June 12, 2025, we executed a $
17.0
 million promissory note with Dignity Health, a related party and joint venture member of Arizona Diagnostic Radiology Group, LLC ("ADRG"). Monthly principal payments of $
0.9
 million begin July 1, 2025, with interest accruing at the Wall Street Journal Prime Rate plus 
2
%. Future distributions from ADRG to Dignity will be applied to the note balance until fully repaid. The note is expected to mature on December 1, 2026. As of September 30, 2025, we recorded $
11.3
 million of the current portion of the notes in Due from Affiliates and $
2.8
 million of the non-current portion in Deposits and Other on our Condensed Consolidated Balance Sheet.
21
Table of Contents
NOTE 3 – 
RECENT ACCOUNTING AND REPORTING STANDARDS
Recently Issued Accounting Pronouncements
In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), 
Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures
. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2024. Early adoption is permitted. We adopted this ASU for the year ended December 31, 2024, and applied the amendments retrospectively to all prior periods presented in our consolidated financial statements. The interim disclosure requirements became effective for us beginning January 1, 2025, and have been reflected in our current period reporting.
In December 2023, the FASB issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the rate reconciliation and income taxes paid disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The ASU will be applicable to the Company’s annual reporting for the year ending December 31, 2025. Early adoption is permitted. The Company expects to adopt this ASU prospectively, and the adoption will affect only disclosures, with no impact on financial condition or results of operations.
In November 2024, the FASB issued Accounting Standards Update (ASU) 2024-03 (“ASU 2024-03”), Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, to enhance the transparency of certain expense disclosures. The amendments in this Update require disclosure of specific expense categories in the notes to the financial statements for both interim and annual reporting periods. The Update also requires disaggregated information about certain prescribed expense categories underlying any relevant income statement expense caption. The amendments in this Update are effective for public entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be adopted either prospectively or retrospectively. We are currently evaluating the impact of this ASU on our consolidated financial statements.
In July 2025, the FASB issued Accounting Standards Update (ASU) 2025-05 (“ASU 2025-05”), Income Taxes (Topic 740): Targeted Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments require disaggregated information about the effective tax rate reconciliation to be presented in both percentages and dollar amounts for specific categories, such as state and local income taxes, foreign tax effects, tax credits, and valuation allowances. The Update also requires additional disclosures of income taxes paid, disaggregated by federal, state, and foreign jurisdictions. The amendments are effective for annual periods beginning after December 15, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, though retrospective application is allowed. We are currently evaluating the impact of this ASU on our consolidated financial statements.
In September 2025, the FASB issued Accounting Standards Update (ASU) 2025-06 (“ASU 2025-06”), Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting for software development costs and enhance the operability of the guidance for different development methods. The amendments remove the prescriptive “project-stage” model and require capitalization of software costs once management has authorized and committed to funding a project and it is probable that the software will be completed and used as intended. The Update also introduces the concept of “significant development uncertainty,” requires application of the property, plant and equipment disclosure requirements to capitalized internal-use software costs, and incorporates website development guidance into Subtopic 350-40. The amendments are effective for annual periods beginning after December 15, 2027, and interim periods within those annual periods. Early adoption is permitted. We are currently evaluating the impact of this ASU on our consolidated financial statements.
 NOTE 4 – 
BUSINESS COMBINATIONS AND RELATED ACTIVITY
Acquisitions
Imaging Center Segment
During the nine months ended September 30, 2025, we completed the acquisition of certain assets of the following entities, which either engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in the California, Texas and New York markets.  These acquisitions are reported as 
22
Table of Contents
part of our Imaging Center segment.  
As of September 30, 2025, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized and remains subject to change, primarily related to the completeness of accrued liabilities, the accuracy of fixed asset valuations, and other customary purchase accounting adjustments. The fair value determination is preliminary and may be updated as additional information becomes available.
Entity 
Date Acquired
Total  Consideration
Property & Equipment
Right of Use Assets
Goodwill
Intangible Assets
Other Assets
Right of Use Liabilities
HALO Centers LLC*
1/2/2025
$
4,201

587
3,238
3,563
50
—
(
3,238
)
Hillcroft Medical Clinic*
3/7/2025
735
278

—

406

50

—

—

North County Radiology Oceanside LLC
4/1/2025
1,702
238
599
1,307
150
7
(
599
)
Faculty Physicians and Surgeons of LLUSM (Palm Imaging)
5/1/2025
1,400
648
—
702
50
—
—
California MSK MSO, LLC (OSS Burbank)
5/1/2025
500
330
—
70
100
—
—
HALO Centers LLC (Indian Wells)
5/1/2025
$
7,850

1,714

2,439

6,072

50

15

(
2,439
)
Kolb Radiology P.C.
7/1/2025
$
26,659

4,799

5,355

22,396

79

155

(
6,125
)
Schonholz and Drossman, LLP
9/1/2025
$
30,101

2,921

5,566

26,790

295

95

(
5,566
)
Total
73,148
11,514
17,197
61,306
824
272
(
17,967
)
*Fair Value Determination is Final
Factors contributing to the recognition of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the acquisition.
Digital Health Segment
See-Mode Technologies
On June 2, 2025, we acquired all of the equity interest in See-Mode Technologies (“See-Mode”), a medical technology company focused on using artificial intelligence to enhance ultrasound-based diagnostics.
 See-Mode’s operations are included in our Digital Health segment for reporting purposes. The transaction was accounted for as the acquisition of a business with a total purchase consideration of approximately $
28.7
 million, including: (i) cash of $
17.9
 million, (ii) a holdback of $
2.0
 million cash to be released 
18
 months after acquisition, and (iii) contingent consideration of $
8.8
 million. We recorded  $
0.2
 million in other net assets, $
5.5
 million in developed technology, $
5.4
 million in IPR&D, $
19.8
 million in goodwill, and $
2.2
 million in deferred tax liabilities in connection with this transaction.
In performing the purchase price allocation, we considered, among other factors, the intended future use of the acquired assets, the historical financial performance, and estimates of the future performance of the See-Mode business. As of September 30, 2025, the valuation of assets acquired and liabilities assumed is preliminary and subject to change, primarily with respect to the valuation of contingent consideration and intangible assets, the completeness of accrued liabilities, the accuracy of fixed asset valuations, and other customary purchase accounting adjustments. The fair value determination will be updated as additional information becomes available during the measurement period.
23
Table of Contents
iCAD, Inc.
On July 17, 2025, we completed the acquisition of all of the outstanding equity interests of iCAD, Inc. (“iCAD”), a global leader in AI-powered breast health solutions. The acquisition integrates iCAD’s commercial, technology, and regulatory capabilities with those of DeepHealth, our wholly owned subsidiary within the Digital Health segment. The transaction strengthens DeepHealth’s position as an industry leader in AI-enabled breast cancer image interpretation and workflow optimization and expands its global market reach.
The transaction was accounted for as the acquisition of a business and was completed through an all-stock exchange, with total purchase consideration of approximately $
110.7
 million based on the fair value of RadNet common stock issued to iCAD shareholders and the fair value of RadNet replacement awards issued in exchange for outstanding iCAD equity awards. 
We preliminarily allocated the purchase price to the assets acquired and liabilities assumed based on their estimated fair values, which resulted in the recognition of goodwill of approximately $
27.2
 million, primarily reflecting expected synergies from integrating iCAD’s technology portfolio, established customer relationships, and assembled workforce. In addition, we recorded identifiable intangible assets related to backlog, developed technology, customer relationships, and trade name totaling approximately $
38.3
 million; deferred tax asset, net of $
30.2
 million, Cash, deposits and others of $
13.9
 million; and property and equipment of $
1.1
 million.
In connection with the iCAD acquisition, the Company identified and measured the fair values of acquired intangible assets, including backlog, trade names, developed technology, in-process research and development (“IPR&D”), and customer relationships. The valuations were performed using the income approach, consistent with market participant assumptions. The income approach incorporated assumptions such as projected revenues, estimated customer attrition, royalty rates, and discount rates reflecting market participant expectations. IPR&D projects were determined to have no material fair value as of the acquisition date. The identified intangible assets were assigned estimated useful lives as follows: backlog — approximately 
4
 years; trade names — approximately 
1
 year; developed technology — approximately 
7
 years; and customer relationships — approximately 
15
 years.
In performing the purchase price allocation, we considered, among other factors, the intended future use of the acquired assets, the historical financial performance, and the expected future contributions of the iCAD business. As of September 30, 2025, the valuation of assets acquired and liabilities assumed is preliminary and subject to change, primarily with respect to the valuation of intangible assets, deferred taxes, and other customary purchase accounting adjustments. The fair value determination will be updated as additional information becomes available during the measurement period.
Formation of majority owned subsidiary and sale of economic interest
On March 21, 2025, we formed Pacific Diagnostic Imaging Group, LLC (“PDRG”), a Delaware limited liability company. On April 1, 2025, we entered into a partnership with Tri-City Healthcare District (“Tri-City”) by selling a 
20
% membership interest in PDRG for cash consideration of $
337,500
. We retained an 
80
% controlling interest in PDRG. The joint venture operates outpatient imaging centers in Southern California. The transaction did not result in a change of control, and no gain or loss was recognized.
NOTE 5 – 
SEGMENT REPORTING
Our chief operating decision maker ("CODM"), who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit and loss statements prepared on a basis not consistent with GAAP. The CODM considers actual to budget and current year actual to prior year actual for revenue and other profit and loss measures on a monthly basis for evaluating performance of each segment and making decisions about allocating capital and other resources to each segment. We do not report balance sheet information by segment since it is not reviewed by our CODM to evaluate segment performance or to make resource allocation decisions.
Our Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.
Our Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. Included in the segment is 
24
Table of Contents
our eRad subsidiary, which designs the underlying critical scheduling, data storage and retrieval systems necessary for imaging center operation.
In the normal course of business, our Imaging Center and Digital Health segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.
The following tables reflect certain financial data for each reportable segment:
Three Months Ended September 30, 2025
Imaging Center
Digital health
Total
Revenues from external customers
$
508,242

$
14,627

$
522,869

Intersegment revenues
—

10,187

10,187

$
508,242

$
24,814

$
533,056

Reconciliation of revenue
Elimination of intersegment revenues
(
10,187
)
Total consolidated revenues
$
522,869

Less:
Other segment items*
$
434,270

$
18,929

$
453,199

Segment profit (loss)
73,972

(
4,301
)
69,671

Reconciliation of segment profit
Depreciation and amortization
$
(
39,799
)
Loss on sale and disposal of equipment and other
(
1,042
)
Severance costs
(
1,441
)
Interest expense
(
17,355
)
Equity in earnings of joint ventures
3,567

Non-cash change in fair value of interest rate swaps
(
2,371
)
Other income
9,044

Income before income taxes
$
20,274

*Other segment items include operating expenses, inclusive of cost of operations and lease abandonment charges.
25
Table of Contents
Three Months Ended September 30, 2024
Imaging Center
Digital health
Total
Revenues from external customers
$
452,367

$
8,774

$
461,142

Intersegment revenues
—

7,593

7,593

$
452,367

$
16,367

$
468,735

Reconciliation of revenue
Elimination of intersegment revenues
(
7,593
)
Total consolidated revenues
$
461,142

Less:
Other segment items*
$
382,381

$
9,418

$
391,799

Segment profit (loss)
69,986

(
644
)
69,342

Reconciliation of segment profit
Depreciation and amortization
$
(
34,979
)
Loss on sale and disposal of equipment and other
(
148
)
Severance costs
(
304
)
Interest expense
(
19,427
)
Equity in earnings of joint ventures
3,595

Non-cash change in fair value of interest rate swaps
(
6,755
)
Other income
5,414

Income before income taxes
$
16,591

*Other segment items include operating expenses, inclusive of cost of operations and lease abandonment charges.
26
Table of Contents
Nine Months Ended September 30, 2025
Imaging Center
Digital health
Total
Revenues from external customers
$
1,457,235

$
35,263

$
1,492,498

Intersegment revenues
—

29,498

29,498

$
1,457,235

$
64,761

$
1,521,996

Reconciliation of revenue
Elimination of intersegment revenues
(
29,498
)
Total consolidated revenues
$
1,492,498

Less:
Other segment items*
$
1,294,559

$
46,716

$
1,341,274

Segment profit (loss)
162,676

(
11,452
)
151,224

Reconciliation of segment profit
Depreciation and amortization
$
(
111,275
)
Loss on sale and disposal of equipment and other
(
3,168
)
Severance costs
(
2,614
)
Interest expense
(
51,783
)
Equity in earnings of joint ventures
10,522

Non-cash change in fair value of interest rate swaps
(
6,433
)
Other income
24,520

Income before income taxes
$
10,993

*Other segment items include operating expenses, inclusive of cost of operations and lease abandonment charges.
27
Table of Contents
Nine Months Ended September 30, 2024
Imaging Center
Digital health
Total
Revenues from external customers
$
1,325,825

$
26,738

$
1,352,563

Intersegment revenues
—

20,118

20,118

1,325,825

46,856

1,372,681

Reconciliation of revenue
Elimination of intersegment revenues
(
20,118
)
Total consolidated revenues
$
1,352,563

Less:
Other segment items*
$
1,140,660

$
28,453

$
1,169,113

Segment profit (loss)
185,165

(
1,715
)
183,450

Reconciliation of segment profit
Depreciation and amortization
(
101,822
)
Loss on sale and disposal of equipment and other
(
735
)
Severance costs
(
797
)
Interest expense
(
61,776
)
Equity in earnings of joint ventures
11,308

Non-cash change in fair value of interest rate swaps
(
7,429
)
Other income
16,248

Income before income taxes
$
29,538

*Other segment items include operating expenses, inclusive of cost of operations and lease abandonment charges.
NOTE 6 – 
CREDIT FACILITIES AND NOTES PAYABLE
At September 30, 2025 we had 
two
 principal secured credit facilities consisting of our Barclays Revolving Credit Facility (as defined below) and our Truist Revolving Credit Facility (as defined below).  Each facility includes a term loan component and a revolving credit facility. At September 30, 2025, we were in compliance with all covenants under our credit facilities.   
Barclays Credit Facility
On April 18, 2024, we entered into a Third Amended and Restated First Lien Credit and Guaranty Agreement (the “Barclays Credit Agreement”), with Barclays Bank Plc and the lenders and financial institutions named therein, which provides for $
875.0
 million of senior secured term loans (the “Barclays Term Loan”) and a $
282.0
 million senior secured revolving credit facility (the “Barclays Revolving Credit Facility”). Our borrowing under the Barclays Revolving Credit Facility is secured by a lien on all of our assets.  
The proceeds from the April 18, 2024 restatement of the Barclays Credit Agreement were used to refinance the $
678.7
 million of term loans outstanding under the prior credit facility, to pay accrued interest through the date of closing, and to pay fees and expenses associated with the refinancing transaction. Total costs incurred in connection with the restatement amounted to approximately $
19.9
 million segregated as follows: $
11.1
 million recognized as discount and deferred finance cost, $
2.1
 million charged to loss on early extinguishment of debt and $
6.7
 million to related expenses.  Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.
On November 26, 2024, we entered into Amendment No. 1 to the Barclays Credit Agreement (the “First Amendment”) with the Barclays Bank Plc and the lenders and financial institutions named therein.  Pursuant to the First Amendment, the interest rates on the term loans and revolving credit facility provided under the Restated Credit Agreement 
28
Table of Contents
have been reduced by 
0.25
%.  Total costs incurred in connection with the first amendment amounted to approximately $
2.4
 million segregated as follows: $
0.6
 million recognized as discount, $
1.8
 million charged to loss on early extinguishment of debt and $
0.1
 million to related expenses.  Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.
On June 11, 2025, we entered into Incremental Amendment No. 2 to the Barclays Credit Agreement (the “Second Amendment”), pursuant to which Barclays Bank Plc, as lender, provided an additional $
100.0
 million, net of a $
1.0
 million discount, of incremental term loan borrowings under our existing senior secured term loan facility, all other terms remained the same.  Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.  Pursuant to the Second Amendment, we are  required to make quarterly principal payments of approximately $
2.4
 million, compared to $
2.2
 million prior to the amendment.  The remaining outstanding principal will be due as a lump-sum payment on April 18, 2031, the maturity date of the incremental term loan.

Barclays Term Loan:
The Barclays Term Loan provides for interest payments based on a base rate, plus an applicable margin.  
During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated:
Period
Base Rate plus Margin
Effective Rate
Before April 18, 2024
SOFR plus 
3.00
%
Alternative Base Rate plus 
2.00
%
8.33
% (credit spread adjustment of 
0.11
%)
10.5
%
After April 18, 2024 to November 26, 2024 
SOFR plus 
2.5
%
Prime Rate plus 
1.5
%
6.45
% (credit spread adjustment of 
0.00
%)
8.5
%
After November 26, 2024
SOFR plus 
2.25
%
Prime Rate plus 
1.25
%
6.4
% (credit spread adjustment of 
0.00
%) 
8.5
%

Barclays Revolving Credit Facility:
The Barclays Revolving Credit Facility is a $
282.0
 million senior secured revolving credit facility.  Associated with the Barclays Revolving Credit Facility is deferred financing costs, net of accumulated amortization, of $
1.5
 million at September 30, 2025.
After we entered the first amendment on November 26, 2024, amounts borrowed under the Barclays Revolving Credit Facility bear interest at either SOFR plus 
2.75
% or the Prime Rate plus 
1.8
% (with step-downs based on attainment of certain first lien net leverage ratio benchmarks).  As of September 30, 2025, the effective interest rate payable on revolving loans under the Barclays Revolving Credit Facility was 
9.00
%.  In addition, a commitment fee of 
0.50
% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility.
We had 
no
 outstanding balance under our $
282.0
 million Barclays Revolving Credit Facility at September 30, 2025 and December 31, 2024.  After reserves of $
7.0
 million for certain letters of credit, $
275.0
 million was available to draw upon as of September 30, 2025.  
The Barclays Revolving Credit Facility terminates on April 18, 2029, unless otherwise accelerated under the terms of the Barclays Credit Agreement.
29
Table of Contents
Truist Credit Facility
On October 7, 2022, our subsidiary New Jersey Imaging Network, Inc. ("NJIN") entered into Second Amended and Restated Revolving Credit and Term Loan Agreement (the “Truist Credit Agreement”), with Truist Bank and the lenders and financial institutions named therein, which provides for a $
150.0
 million term loan (the "Truist Term Loan") and a $
50.0
 million revolving credit facility (the “Truist Revolving Credit Facility”). The Truist Credit agreement is secured by the assets of NJIN.
Truist Term Loan:
The Truist Term Loan currently bears interest at SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. At September 30, 2025 the applicable margin for SOFR was 
1.5
%.
We are required to make quarterly principal payments of $
2.8
 million, which increases by $
0.9
 million at scheduled intervals, with the remaining balance to be paid at maturity. The Truist Term Loan will mature on October 10, 2027 unless otherwise accelerated under the terms of the Truist Credit Agreement.
Truist Revolving Credit Facility:
The Truist Revolving Credit Facility is a $
50.0
 million secured revolving credit facility. Associated with the Truist Revolving Credit Facility are deferred financing costs, net of accumulated amortization, of $
0.3
 million at September 30, 2025. 
Amounts borrowed under the Truist Revolving Credit Facility bear interest at either SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. In addition, a commitment fee of 
0.30
% per annum accrues on the unused revolver commitments under the Truist Revolving Credit Facility.
We had 
no
 balance outstanding under our $
50.0
 million Truist Revolving Credit Facility at September 30, 2025 and December 31, 2024. With 
no
 letters of credit reserved against the facility, the full $
50.0
 million was available to draw upon as of September 30, 2025.  
The Truist Revolving Credit Facility terminates on October 7, 2027, unless otherwise accelerated under the terms of the Truist Credit Agreement.  
Equipment Notes Payable
We have issued certain notes payable in connection with the purchase of equipment previously leased under operating leases. 
Debt Obligations
As of September 30, 2025 and December 31, 2024 our term loan debt and other obligations are as follows (in thousands):
September 30,
2025
December 31,
2024
Barclays Term Loans collateralized by RadNet's tangible and intangible assets
$
963,559

$
870,625

Discount on Barclays Term Loans
(
12,319
)
(
12,929
)
Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets
126,562

135,000

Discount on Truist Term Loan Agreement
(
528
)
(
726
)
Equipment notes payable at 
3.6
% to  
7.2
%, due through 2029, collateralized by medical equipment
19,066

24,296

Total debt obligations
1,096,340

1,016,266

Less: current portion
(
25,454
)
(
24,692
)
Long term portion of debt obligations
$
1,070,886

$
991,574

NOTE 7 – 
STOCK-BASED COMPENSATION
Stock Incentive Plans
30
Table of Contents
We have 
one
 long-term equity incentive plan, the RadNet, Inc. Equity Incentive Plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approval by our stockholders at our annual stockholders meeting on June 7, 2023 (the “Restated Plan”). We have reserved for issuance under the Restated Plan 
20,100,000
 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units and stock appreciation rights.
Our stock-based compensation consists of various types of awards, each accounted for separately. There is no overlap between Options, DeepHealth options, Restricted stock awards (RSAs) and Restricted stock units (RSUs), performance stock units (PSUs), and performance stock options (PSOs).
Options
Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations.  Stock options generally vest over 
3
 to 
5
 years and expire 
5
 to 
10
 years from the date of grant.
The following summarizes all of our option transactions for the nine months ended September 30, 2025:
Outstanding Options
Under the 2006 Plan
Shares
Weighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in thousands)
Balance, December 31, 2024
840,917

$
17.19

Granted
—

—

Exercised
(
62,796
)
8.87

Balance, September 30, 2025
778,121

17.86

4.89
$
45,401

Exercisable at September 30, 2025
778,121

17.86

4.89
$
45,401

Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2025 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2025.
DeepHealth Options
During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted options to acquire 
412,434
 shares at a grant date fair value of $
16.93
 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2025, there were 
65,208
 stock options outstanding under the DeepHealth Plan, all of which were exercisable. These options had a weighted average remaining contractual life of 
4.0
 years and an aggregate intrinsic value of approximately $
5.0
 million.
Options issued in replacement of original DeepHealth options as a result of our acquisition are not included in the share count under the Restated Plan.
iCAD Options
During the third quarter of fiscal 2025, in connection with the completion of the iCAD acquisition, we granted options to acquire 
163,838
 shares to iCAD employees in replacement of their stock options that were outstanding as of the closing date.
31
Table of Contents
The following summarizes all of our iCAD option transactions from the date of acquisition (July 17, 2025) through September 30, 2025:
Outstanding Options
Under the 2006 Plan
Shares
Weighted Average
Exercise price
Per Common Share
Weighted Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic
Value
(in thousands)
Balance, July 17, 2025
—

$
—

Granted
163,838

30.96

Exercised
(
55,866
)
30.44

Canceled, forfeited or expired
(
721
)
41.28

Balance, September 30, 2025
107,251

31.17

6.89
$
4,831

Exercisable at September 30, 2025
90,737

32.15

6.62
$
3,998

Restricted Stock Awards ("RSAs") and Restricted Stock Units ("RSUs")
The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended September 30, 2025:

RSAs and RSUs
Weighted-Average
Remaining
Contractual
Term (Years)
Weighted-Average
Fair Value per Share
RSAs and RSUs unvested at December 31, 2024
687,655

$
35.31

Granted
969,978

$
73.66

Vested
(
698,290
)
$
52.35

Forfeited or Canceled
(
19,824
)
$
46.61

RSAs and RSUs unvested at September 30, 2025
939,519

1.74
$
58.37

We determine the fair value of all RSAs and RSUs based on the closing price of our common stock on the award date.
Performance based stock units ("PSUs")
In October 2024, we granted certain employees PSUs with a target award of 
35,522
 shares of our common stock. The PSUs will vest in 
five
 equal parts, on each anniversary of the grant date based on continuous service, with the number of shares earned (
0
% to 
100
% of the target award)  depending on the level of achievement against a predefined performance condition, which must be evaluated by management no later than the seventh anniversary of the grant date. As of September 30, 2025, based on the performance to date, all 
35,522
 shares are expected to vest.
In January 2023, we granted certain employees PSUs with a target award of 
60,685
 shares of our common stock with a fair value of $
18.64
. The PSUs will vest in 
two
 equal parts, starting 
three years
 from the grant date based on continuous service, with the number of shares earned (
0
% to 
200
% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. In March of 2024, based on the performance condition being achieved, the board of directors issued 
121,370
 shares.
Performance based stock options ("PSOs")
In January 2023, we granted certain employees PSOs with a potential to purchase a maximum of 
235,227
 shares of our common stock with a strike price of $
18.64
. The PSOs will vest in 
three
 equal parts, starting 
three years
 from the grant date based on continuous service, with the number of shares earned (
0
% to 
100
% of the target award) depending upon the extent to which we achieve a performance condition as determined the board of directors over the period from January 1, 2023 through December 31, 2023. In March 2024, based on the performance condition being achieved, the board of directors issued 
235,227
 options.
Shares available
Of the 
20,100,000
 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2025, there remain approximately 
2,196,122
 shares available under the Restated Plan for future issuance.
32
Table of Contents
NOTE 8 – 
SUBSEQUENT EVENTS
Remote Diagnostic Imaging Partners, LLC
On October 1, 2025, we acquired substantially all of the assets of Remote Diagnostic Imaging Partners, LLC for total purchase consideration of approximately $
4.5
 million, payable in shares of RadNet, Inc. common stock. The acquired business provides technology and operational support services related to radiology imaging.
ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q (this "report") and with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the "SEC")(the "Annual Report").
As used in this Quarterly Report on Form 10-Q, the terms "RadNet," "we," "us," and "our" refer to RadNet, Inc., a Delaware corporation, and where appropriate, our consolidated subsidiaries. 
Forward-Looking Statements
This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.
In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Forward-looking statements in this report include, among others, statements we make regarding:
•
expectations concerning domestic and global economic conditions, rates of inflation, or changes in interest rates;
•
anticipated trends in our revenues, operating expenses or capital expenditures, and our financial guidance;
•
expected timing and potential impact of regulatory changes affecting our business; 
•
expected future market acceptance for our products or services, and our competitive strengths in the markets we serve;
•
our ability to successfully acquire and integrate new businesses, and achieve expected benefits, synergies or operating results from those acquisitions; and
•
economics and cost savings anticipated to be derived from our investments in artificial intelligence and machine learning products and solutions.
Forward-looking statements are neither historical facts nor assurances of future performance.  Because forward-looking statements relate to the future, they are inherently subject to known and unknown risks, uncertainties and other factors that are difficult to predict and out of our control.  Our actual results, level of activity, performance or achievements may be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  Important factors that could cause our actual results to differ materially from those indicated or implied in our forward-looking statements include the factors included in “Risk Factors,” in our Annual Report as supplemented by the information in Part II– Item 1A below. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.
Any forward-looking statement in this report is based on information currently available to us and speaks only as of the date of this report.  We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report or any unanticipated events which 
33
Table of Contents
may cause actual results to differ from those expressed or implied by the forward-looking statements contained in this report, except as required by law.
Overview
We are a national provider of diagnostic imaging services in the United States. At September 30, 2025, we operated directly or indirectly through joint ventures with hospitals, 407 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Internationally, our subsidiary The HLH Imaging Group Limited, provides teleradiology services for remote interpretation of images on behalf of providers within the framework of the United Kingdom's National Health Service.
In addition to our imaging business, we have established a Digital Health business segment during our 2024 fiscal year, which combines our former Artificial Intelligence (“AI”) business segment with our eRad, Inc. business.  Our Digital Health segment develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology. The portfolio of software solutions is anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology and DeepHealth OS, a cloud-native operating system that helps operate all aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management. 
In addition, we are using AI to develop solutions that employ machine learning to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care, initially in the fields of screening for breast, prostate, lung and colon cancers. Our DeepHealth, Inc. subsidiary has received clearance from the U.S. Food and Drug Administration ("FDA") for use of its SaigeQ ”triage”/workflow products, the SaigeDX advanced diagnostic product and the Saige-Density breast density assessment software for screening breast mammography, which we have begun to roll out in certain markets as an Enhanced Breast Cancer Detection solution. Our Aidence Holding B.V. subsidiary is developing solutions for interpretation of chest and lung computed tomography ("CT") scans for lung cancer screening. It has received the CE mark for its solution and has existing customers in seven European countries, with its largest concentration in the United Kingdom, and plans to submit an application for FDA clearance to sell in the United States. Our Quantib B.V. subsidiary is primarily focused on interpretation of prostate magnetic resonance imaging ("MRI") for widespread prostate cancer screening. Quantib’s prostate MRI post-processing software has both FDA clearances and European CE marking. Our Digital Health segment provides these solutions to RadNet and to over 400 customers in the United States, Europe, and Israel.
As part of our continued strategic expansion in Digital Health, we recently completed two acquisitions: iCAD, Inc., a provider of AI-powered breast health solutions, and See-Mode Technologies, a medical technology company focused on enhancing ultrasound-based diagnostics through artificial intelligence. We are currently in the process of integrating both businesses into our Digital Health segment.
Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our financial statements included in this report.
Recent Developments
The following table shows our imaging centers in operation and revenues for the nine months ended September 30, 2025 and 2024:

Nine Months Ended September 30,

2025
2024
Centers in operation
407
399 
Net revenues (millions)
$
1,492 
$
1,353 

34
Table of Contents
Our
 imaging services include MRI, CT, positron emission tomography ("PET"), nuclear medicine, mammography, ultrasound, diagnostic radiology ("X-ray"), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a key point of differentiation from our competitors. 
 The multi-modality offering provides a “one-stop” solution for our customers and referral sources. It also diversifies our revenue base, and reduces our exposure to changes in reimbursement rates for certain imaging modalities. 
Our revenue is derived from a diverse mix of payors, including private payors and commercial insurance companies, managed care capitated payors, and government payors, such as Medicare and Medicaid. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. Our total service fee revenue, net of contractual allowances and discounts, and implicit price concessions for the three and nine months ended September 30, 2025 and 2024 received from our various payors is summarized in the following table (in thousands):
In Thousands
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Commercial insurance
$
287,769 
$
255,376 
$
829,295 
$
752,515 
Medicare
123,254 
102,853 
347,641 
298,001 
Medicaid
13,470 
10,894 
37,735 
32,804 
Workers' compensation/personal injury
11,347 
10,233 
32,460 
33,088 
Other payors
29,962 
25,366 
87,064 
77,336 
Management fee revenue
7,044 
6,241 
20,011 
18,255 
Other revenue
18,580 
16,616 
44,632 
35,514 
Revenue under capitation arrangements
31,443 
33,563 
93,660 
105,050 
Total service revenue
$
522,869 
$
461,142 
$
1,492,498 
$
1,352,563 
Our revenue is not always consistent across each quarter. We generally experience the lowest volumes of procedures and the lowest level of revenue during the first quarter of each year. This is primarily the result of two factors. First, our volumes and revenue are typically impacted by winter weather conditions in our northeastern operations. It is common for snowstorms and other inclement weather to result in patient appointment cancellations and, in some cases, imaging center closures. Second,  in recent years, we have observed greater participation in high deductible health plans by patients. As these high deductibles reset in January for most of these patients, we have observed that patients utilize medical services less during the first quarter, when securing medical care will result in significant out-of-pocket expenditures.
35
Table of Contents
Acquisitions
During the nine months ended September 30, 2025, 

we completed the acquisition of certain assets of entities which engage directly in the practice of radiology or in associated businesses for an aggregate consideration of $73.1 million. These acquisitions include:
HALO Centers LLC*: 1 imaging center in California; 
Hillcroft Medical Clinic*: 1 imaging center in Sugar Land, Texas;
North County Radiology Oceanside LLC: 1 imaging center in California;
Faculty Physicians and Surgeons of LLUSM (Palm Imaging): 1 imaging center in California;
California MSK MSO, LLC (OSS Burbank): 1 imaging center in California; and
HALO Centers LLC (Indian Wells): 1 imaging center in California
Kolb Radiology P.C.: 3 imaging centers in New York
Schonholz and Drossman, LLP: 1 imaging centers in New York
See Note 4, Business Combinations and Related Activity, in the notes accompanying our financial statements in this report for additional information, including the fair value determination of the acquired assets and assumed liabilities, associated with these acquisitions.
36
Table of Contents
Joint Venture Activity
At September 30, 2025, 37% of our imaging centers were operating as joint ventures with large health care providers. We manage the day-to-day operations for these joint ventures and perform most management services in exchange for a management fee. We charged management service fees from the centers underlying these joint ventures of approximately $6.5 million and $5.9 million for the three months ended September 30, 2025 and 2024, respectively, and approximately $19.1 million and $17.8 million for the nine months ended September 30, 2025 and 2024, respectively.
For information on our investment in unconsolidated joint ventures, key balance sheet data and income statement data for the unconsolidated joint ventures, see Note 2, Significant Accounting Policies – Investment in Joint Ventures in the notes accompanying our financial statements included in this report.
 Critical Accounting Policies
The SEC defines critical accounting estimates as those that (a) are most important to the portrayal of a company’s financial condition and results of operations and (b) require management’s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 of the notes accompanying our financial statements included in this report and in our Annual Report, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management’s judgments and estimates are described below.
Use of Estimates
The financial statements included in this report were prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management’s control. As a result, actual amounts could materially differ from these estimates.
Revenues
Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenue is recorded during the period our obligations to provide diagnostic services are satisfied, which is generally over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations, changes in business and economic conditions, and the frequent changes in managed care contractual terms resulting from contract re-negotiations and renewals.
As it relates to the Consolidated Medical Group (as defined in Note 1 of the notes accompanying our financial statements included in this report), this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.
Our service fee revenue is based upon our management's estimate of amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under Medicare, Medicaid, managed care and commercial insurance plans are based upon historical collection experience of the payments received from such payors in accordance with 
37
Table of Contents
the underlying contractual agreements. Revenue related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenue at the estimated amounts we expect to collect.
Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.  Our estimates and assumptions related to revenue recognition did not change materially for the quarter ended September 30, 2025.
Accounts Receivable
Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.  Our estimates and assumptions for allowances on our account receivable did not change materially during the quarter ended September 30, 2025.
Business Combination
We evaluate all acquisitions in accordance with the accounting guidance under ASC 805, Business Combinations. Once a purchase has been determined to be the acquisition of a business, we are required to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. Any portion of the purchase consideration transferred in excess of the net of the acquisition date fair values of the assets acquired and the liabilities assumed, is allocated to goodwill.  The allocation requires our management to make estimates of the value of various assets acquired and liabilities assumed.  While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.
Goodwill and Indefinite Lived Intangibles
Goodwill at September 30, 2025 totaled $827.5 million.  Indefinite Lived Intangible Assets at September 30, 2025 were $18.5 million and are associated with the value of certain trade name intangibles and in process research and development ("IPR&D"). Goodwill, trade name intangibles and IPR&D are recorded as a result of business combinations. When we determine the carrying value of goodwill for a reporting unit exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately.  Our annual impairment test of goodwill, IPR&D and trade name noted no impairment as of October 1, 2024, and we have not identified any other indicators of impairment through September 30, 2025.
Recent Accounting Standards
See Note 3, Recent Accounting and Reporting Standards to the financial statements included in this report for further information.
Results of Operations
Result Summary
The following table summarizes our consolidated results of operations and other financial information:
38
Table of Contents
In Thousands
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025
2024
2025
2024
Operating Revenue
Imaging Center
$
508,242 
$
452,367 
$
1,457,235 
$
1,325,825 
Digital Health
24,814 
16,367 
64,761 
46,856 
Intersegment eliminations
(10,187)
(7,593)
(29,498)
(20,118)
Total service revenue
$
522,869 
$
461,141 
$
1,492,498 
$
1,352,563 
Operating income
Imaging Center
$
73,972 
$
69,986 
$
162,676 
$
185,165 
Digital Health
$
(4,301)
$
(644)
$
(11,452)
$
(1,715)
Total Operating income
$
69,671 
$
69,342 
$
151,224 
$
183,450 
Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024
Imaging Center Segment
We have developed our medical imaging centers segment through a combination of organic growth, acquisitions and joint venture formations. In the discussion below same center metrics are based on imaging centers that were in operation throughout the period of April 1, 2024 through September 30, 2025. Excluded amounts relate to imaging centers that were acquired or divested between April 1, 2024 through September 30, 2025. The revenue analysis presented below includes intersegment revenue prior to elimination.
Total Revenue 
In Thousands
Three Months Ended September 30,
Revenue
2025
2024
$ Increase
% Change
Total
$508,242
$452,367
$55,875
12.4%
Same Center
$490,029
$447,059
$42,970
9.6%
Excluded
$18,213
$5,308
—
—
Our 9.6% increase in same center revenue over the same period last year was driven by increases in fees charged per imaging procedure and same center total procedure volume growth of 4.4%, inclusive of rises in routine and advanced modality imaging procedures of 2.7% and 9.1%, respectively. The increase in revenue was largely attributable to product mix, as advanced imaging represented a greater portion of overall procedures. Within advanced imaging, MRI increased by 11.1%, CT by 5.3%, and PET/CT by 14.9% on a same-store basis. The Enhanced Breast Cancer Detection program, an AI-powered diagnostic solution, also contributed to revenue growth.
Including non-consolidated joint ventures where we are a minority owner, same center total procedure volume increased approximately 4.9%, inclusive of rises in routine and advanced modality imaging procedures of 3.1% and 9.1%, respectively. We provide this additional information to reflect trends across all centers we operate or manage, consistent with how management evaluates overall business performance.
Operating Expenses
Total operating expenses for the three months ended September 30, 2025 increased approximately $53.5 million, or 13.1%, to $460.8 million for the three months ended September 30, 2025 from $407.2 million for the three months ended September 30, 2024. The following table breaks down our cost of operations and total operating expenses for the three months ended September 30, 2025 and 2024 (in thousands): 
39
Table of Contents

Three Months Ended
September 30,

2025
2024
Salaries and professional reading fees, excluding stock-based compensation
$
271,611 
$
243,067 
Stock-based compensation
6,772 
4,195 
Building and equipment rental
32,713 
31,104 
Medical supplies
30,068 
26,668 
Lease abandonment charges
2,819 
— 
Other operating expenses 
*
80,100 
69,754 
Cost of operations
424,083 
374,788 
Depreciation and amortization
35,320 
32,032 
Loss on sale and disposal of equipment
1,009 
153 
Severance costs
351 
271 
Total operating expenses
$
460,763 
$
407,244 
    *
Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.
The discussion below provides additional information and analysis on changes in our various operating expenses for the three months ended September 30, 2025 and 2024 (in thousands): 
Salaries and professional reading fees, excluding stock-based compensation and severance
In Thousands
Three Months Ended September 30,
Salaries and Professional Fees
2025
2024
$ Increase/(Decrease)
% Change
Total 
$271,611
$243,067
$28,544
11.7%
Same Center
$264,561
$240,528
$24,033
10.0%
Excluded 
$7,050
$2,539
—
—
In response to higher procedure volumes, we increased staffing levels across clinical, administrative, and technical functions to support the influx of patients. Compensation-related expenses were further impacted by increased 401K match contributions and more vacation and paid time off taken during the period. We also continued to experience wage inflation across the board, driven by a competitive labor market and the October 2024 increase in California’s minimum wage for healthcare workers. Additionally, higher workers’ compensation insurance premiums contributed to the overall rise in staffing costs. Overall, the increase in compensation expenses remained generally in line with our same center revenue growth.
Stock-based compensation
Stock-based compensation for the three months ended September 30, 2025 increased approximately $2.6 million, or 61.4%, to $6.8 million from $4.2 million for the three months ended September 30, 2024.  The increase is primarily due to a greater number of shares granted and higher grant-date fair values compared to prior-year period.
Building and equipment rental
In Thousands
Three Months Ended September 30,
Building & Equipment Rental
2025
2024
$ Increase/(Decrease)
% Change
Total
$32,713
$31,104
$1,609
5.2%
Same Center 
$30,799
$30,095
$704
2.3%
Excluded 
$1,914
$1,009
—
—
Building and equipment rental expense on a same-center basis increased slightly, primarily due to higher rent and common area maintenance charges.
40
Table of Contents
Medical supplies
In Thousands
Three Months Ended September 30,
Medical Supplies Expense
2025
2024
$ Increase/(Decrease)
% Change
Total
$30,068
$26,668
$3,400
12.7%
Same Center
$28,187
$26,593
$1,594
6.0%
Excluded 
$1,881
$75
—
—
Consistent with the shift in our procedural mix toward more advanced imaging, medical supplies expense increased at a higher rate than revenue growth. The growth in PET/CT procedures, particularly for prostate cancer and suspected Alzheimer’s studies, drove higher utilization of high-cost isotope tracers, contributing to the increase. In addition, price increases for these tracers further elevated medical supplies expense compared to the prior year.
Other operating expenses
In Thousands
Three Months Ended September 30,
Other Operating Expenses
2025
2024
$ Increase/(Decrease)
% Change
Total
$80,100
$69,754
$10,346
14.8%
Same Center
$76,582
$68,903
$7,679
11.1%
Excluded 
$3,518
$851
—
—

Other operating expenses increased primarily due to a $7.3 million rise in outside services. This increase was driven by expanded contact center support related to acquisitions and growing patient demand, as well as higher legal and consulting costs associated with transaction activities and operational initiatives.  The remaining increase was attributable to other operating expense categories. The investments reflect our continued focus on technology-driven enhancements aimed at supporting long-term operational efficiency across the organization.
Additional segment operating and non-operating expenses
In Thousands
Three Months Ended September 30,
2025
2024
$ Increase/(Decrease)
% Change
Depreciation and amortization
$35,320
$32,032
$3,288
10.3%
Loss on disposal of equipment and other
$1,009
$153
$856
559.5%
Non-cash change in fair value of interest rate hedge
$2,371
$6,755
(4,384)
(64.9)%
Other income
($8,992)
($8,233)
(759)
9.2%
Severance
$351
$271
80
29.5%
41
Table of Contents
The increase in depreciation expense was the result of our higher depreciable asset base.
Other income for the three months ended September 30, 2025 included $8.9 million of money market interest income.
Other income for the three months ended September 30, 2024 included money market interest income of $9.6 million, partially offset by an impairment of non-marketable securities of $1.2 million.
In Thousands
Three Months Ended September 30,
2025
2024
$ Increase/(Decrease)
% Change
Interest income
(8,923)
(9,580)
$657
(6.9)%
Debt restructuring and extinguishment expenses
0
147
$(147)
(100.0)%
Other non-operating losses (income)
(67)
1,200
$(1,267)
(105.6)%
Total other income
$(8,990)
$(8,233)
$(757)
9.2%
Interest expense
In Thousands
Three Months Ended September 30,
Interest expense
2025
2024
$ Increase/(Decrease)
% Change
Total interest expense
$
17,355 
$
19,427 
$(2,072)
(10.7)
%
Interest related to derivatives*
(2,247)
(2,068)
Interest expense related to amortization**
771 
795 
Adjusted interest expense***
18,831 
20,700 
(1,869)
(9.0)
%
*Includes payments from 2019 Swaps (as defined in the notes to our condensed consolidated financial statements) and Swaps amortization
**Includes noncash amortization of deferred loan costs and discount on issuance of debt
***Includes interest related to our term loans, revolving credit line, notes, and other
The decrease in interest expense was primarily due to the repricing transaction of our Barclays Revolving Credit Facility (as defined in the notes to our condensed consolidated financial statements) in the fourth quarter of 2024, which resulted in lower interest rates compared to the same period in the prior year. This benefit was partially offset by the $100.0 million of incremental term loan borrowings under our existing Barclays Revolving Credit Facility in the second quarter of 2025. See Note 6 Credit Facilities and Notes Payable included in the notes to our condensed consolidated financial statements.
During the three months ended September 30, 2025, interest rates were above the arranged rates in our 2019 Swaps for most of the year, and we received $2.5 million in cash payments from our 2019 Swaps counterparties, which was reported as a component of interest expense. See the Derivative Instruments section of Note 2, Significant Accounting Policies, in the notes accompanying in our Annual Report and Part 1, Item 3 —  "Quantitative and Qualitative Disclosure About Market Risk" below for more details on our derivative transactions.
Non-cash change in fair value of interest rate hedge
In 2020, we determined that the cash flows from the 2019 Swaps did not match the cash flows of our Barclays Term Loan (as defined in the notes to our condensed consolidated financial statements) and were therefore ineffective as cash flow hedges.  Since that time, in accordance with accounting guidelines, all changes in fair value are being recognized in other income and expense. 
42
Table of Contents
The fair value of the 2019 Swaps at September 30, 2025 was a net asset of $0.7 million compared to a net asset of $3.1 million at June 30, 2025, resulting in a loss of $2.4 million during the three months ended September 30, 2025. This change in fair value was driven by market expectations of continued declines in interest rates over the remaining term of the 2019 Swaps.
 Equity in earnings from unconsolidated joint ventures
For the three months ended September 30, 2025 and 2024, we recognized equity in earnings from unconsolidated joint ventures in the amount of $3.6 million and $3.6 million, respectively, remaining essentially flat year over year.
Net income attributable to noncontrolling interests 
At September 30, 2025, our consolidated subsidiaries operated 356 imaging centers of which 101 were not wholly-owned and thus a portion of their operating results were attributable to noncontrolling interests. At September 30, 2024, our consolidated subsidiaries included 345 centers of which 98 were not wholly-owned. 
For the three months ended September 30, 2025, we recognized net income attributable to noncontrolling interests of $8.5 million versus $9.0 million for the three months ended September 30, 2024, respectively, remaining essentially flat year over year.
As noncontrolling interests only represent a portion of our imaging center business, and excludes our Digital Health segment, which generated losses of $9.9 million for the three months ended September 30, 2025, we do not expect changes in net income attributable to noncontrolling interests to correlate with changes in consolidated operating income or pretax income.
Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024 
In the discussion below, same center metrics are based on imaging centers that were in operation throughout the period of January 1, 2024 through September 30, 2025. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2024 through September 30, 2025.
Total Revenue
In Thousands
Nine Months Ended September 30,
Revenue
2025
2024
$ Increase
% Change
Total 
$1,457,236
$1,325,906
$131,330
9.9%
Same Center
$1,345,377
$1,272,762
$72,615
5.7%
Excluded
$111,859
$53,144
—
—
Our 5.7% increase in same center revenue over the same period last year was driven by increases in fees charged per imaging procedure and same center total procedure volume growth of 1.6% inclusive of rises in advanced modality imaging procedures of 5.9%, and a 0.1% increase in routine modality imaging. The increase in revenue was largely attributable to product mix, as advanced imaging was a greater portion of overall procedures. Within advanced imaging, MR increased by 6.5%, CT by 4.3%, and PET/CT by 12.8% on a same-store basis. The Enhanced Breast Cancer Detection (EBCD) program, an AI-powered diagnostic solution, also contributed to revenue growth.
Including non-consolidated joint ventures in which we hold a minority interest, same-center total procedure volume increased approximately 2.2%, inclusive of rises in routine and advanced modality imaging procedures of 0.7% and 6.4%, respectively. We provide this information to present trends across all centers we operate or manage, consistent with how management evaluates overall business performance.
Operating Expenses
Total operating expenses for the nine months ended September 30, 2025 increased approximately $154.3 million, or 12.7%, to $1,370.4 million for the nine months ended September 30, 2025 from $1,216.1 million for the nine months ended September 30, 2024. The following table breaks down our cost of operations and total operating expenses for the nine months ended September 30, 2025 and 2024 (in thousands): 
43
Table of Contents

Nine Months Ended September 30,

2025
2024
Salaries and professional reading fees, excluding stock-based compensation
$
800,451 
$
731,133 
Stock-based compensation
38,092 
19,614 
Building and equipment rental
95,643 
89,827 
Medical supplies
90,990 
75,146 
Lease abandonment charges
8,330 
— 
Other operating expenses 
*
231,555 
204,822 
Cost of operations
1,265,061 
1,120,542 
Depreciation and amortization
100,799 
94,095 
Loss on sale and disposal of equipment
3,220 
739 
Severance costs
1,356 
720 
Total operating expenses
$
1,370,436 
$
1,216,096 
    *
Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.
Salaries and professional reading fees, excluding stock-based compensation and severance
In Thousands
Nine Months Ended September 30,
Salaries and Professional Fees
2025
2024
$ Increase/(Decrease)
% Change
Total 
$800,451
$731,133
$69,318
9.5%
Same Center
$757,084
$706,136
$50,948
7.2%
Excluded
$43,367
$24,997
—
—
In response to higher procedure volumes, we increased staffing levels across clinical, administrative, and technical functions to support the influx of patients. This included permanent headcount growth as well as a significant number of temporary hires to keep our centers operating smoothly during the first quarter of 2025. Compensation-related expenses were further impacted by increased 401K match contributions and more vacation and paid time off taken during the period. We also continued to experience wage inflation across the board, driven by a competitive labor market and the October 2024 increase in California’s minimum wage for healthcare workers. Additionally, higher workers’ compensation insurance premiums contributed to the overall rise in staffing costs.
Stock-based compensation
Stock-based compensation for the nine months ended September 30, 2025 increased approximately $18.5 million, or 94.2%, to $38.1 million from $19.6 million for the nine months ended September 30, 2024.  The increase is primarily due to a greater number of shares granted and higher grant-date fair values compared to prior-year period.
Building and equipment rental
In Thousands
Nine Months Ended September 30,
Building & Equipment Rental
2025
2024
$ Increase/(Decrease)
% Change
Total
$95,643
$89,827
$5,816
6.5%
Same Center 
$85,353
$83,339
$2,014
2.4%
Excluded
$10,290
$6,488
—
—
Building and equipment rental expense on a same-center basis increased slightly, primarily due to higher rent and common area maintenance charges.
Medical supplies
44
Table of Contents
In Thousands
Nine Months Ended September 30,
Medical Supplies Expense
2025
2024
$ Increase/(Decrease)
% Change
Total
$90,990
$75,146
$15,844
21.1%
Same Center
$78,791
$71,294
$7,497
10.5%
Excluded
$12,199
$3,852
—
—
Consistent with the shift in our procedural mix toward more advanced imaging, medical supplies expense increased at a higher rate than revenue growth. The growth in PET/CT procedures, particularly for prostate cancer and suspected Alzheimer’s studies, drove higher utilization of high-cost isotope tracers, contributing to the increase. In addition, price increases for these tracers further elevated medical supplies expense compared to the prior year.
Lease abandonment charges
We closely monitor patient levels at our imaging centers and occasionally divest or shut down centers to maximize utilization rates. We may abandon low utilization leases and divert the patients to nearby centers. During the nine months ended September 30, 2025, we closed several imaging centers with lower utilization and recognized lease abandonment charges of approximately $8.3 million in our Imaging Center segment. Of these amounts, $6.5 million were related to right-of-use assets impairment and $1.9 million were related to the write-off of leasehold improvements for the nine months ended September 30, 2025.
Other operating expenses
In Thousands
Nine Months Ended September 30,
Other Operating Expenses
2025
2024
$ Increase/(Decrease)
% Change
Total
$231,555
$204,822
$26,733
13.1%
Same Center
$208,723
$196,253
$12,470
6.4%
Excluded Sites
$22,832
$8,569
—
—
Other operating expenses increased primarily due to a $16.9 million rise in outside services. This increase was driven by expanded contact center support related to acquisitions and growing patient demand, as well as higher legal and consulting costs associated with transaction activities and operational initiatives.  The remaining increase was attributable to other operating expense categories. The investments reflect our continued focus on technology-driven enhancements aimed at supporting long-term operational efficiency across the organization.
Additional segment operating and non-operating expenses:
In Thousands
Nine Months Ended September 30,
2025
2024
$ Increase/(Decrease)
% Change
Depreciation and amortization
$100,799
$94,095
$6,704
7.1%
Loss on disposal of equipment and other
$3,220
$739
$2,481
335.7%
Non-cash change in fair value of interest rate hedge
$6,433
$7,429
$(996)
(13.4)%
Other income
$(24,474)
$(12,752)
$(11,722)
91.9%
Severance
$1,356
$720
$636
88.3%
45
Table of Contents
The increase in depreciation expense was the result of our higher depreciable asset base.
The fair value of the 2019 Swaps at September 30, 2025 was a net asset of $0.7 million compared to a net asset of $7.1 million at December 31, 2024, resulting in a loss of $6.4 million during the nine months ended September 30, 2025. This change in fair value was driven by market expectations of continued declines in interest rates over the remaining term of the 2019 Swaps.
Other income for the nine months ended September 30, 2025 included money market interest income of $24.4 million. Other income for the nine months ended September 30, 2024 included money market interest income of $22.7 million, partially offset by an impairment of non-marketable securities of $1.2 million and debt extinguishment and restructuring charges of $8.9 million, which related to refinancing of our Barclays credit facility. See Note 6 Credit Facilities and Notes Payable included in the notes to our condensed consolidated financial statements.
In Thousands
Nine Months Ended September 30,
2025
2024
$ Increase/(Decrease)
% Change
Interest income
(24,407)
(22,681)
$(1,726)
7.6%
Debt restructuring and extinguishment expenses
0
8,909
$(8,909)
(100.0)%
Others
(67)
1,019
$(1,086)
(106.6)%
Total other income
$(24,474)
$(12,752)
$(11,722)
91.9%
 Interest income for the nine months ended September 30, 2025 increased approximately $1.7 million, or 7.6%, to $24.4 million from $22.7 million for the nine months ended September 30, 2024.  The increase is primarily due to higher average cash balance in our money market account for the nine months ended September 30, 2025

Interest expense
In Thousands
Nine Months Ended September 30,
Interest Expense
2025
2024
$ Increase/(Decrease)
% Change
Total Interest Expense
$
51,783 
$
61,776 
$(9,993)
(16.2)
%
Interest expense related to derivatives*
(4,305)
776 
Interest expense related to amortization**
2,242 
2,336 
Adjusted Interest Expense***
53,846 
58,664 
(4,818)
(8.2)
%
*Includes payments from 2019 Swaps and Swaps amortization
**Includes noncash amortization of deferred loan costs and discount on issuance of debt
***Includes interest related to our term loans, revolving credit line, notes, and other
The decrease in interest expense was primarily due to the repricing transaction of our Barclays Revolving Credit Facility (as defined in the notes to our condensed consolidated financial statements) in the fourth quarter of 2024, which resulted in lower interest rates compared to the same period in the prior year. This benefit was partially offset by the $100.0 million of incremental term loan borrowings under our existing Barclays Revolving Credit Facility in the second quarter of 2025. See Note 6 Credit Facilities and Notes Payable included in the notes to our condensed consolidated financial statements.
  During the nine months ended September 30, 2025, interest rates were above the arranged rates in our 2019 Swaps for most of the year and we received payment of $7.2 million in cash payments from our 2019 swap counterparties, which was reported as a component of interest expense. See the Derivative Instruments section of Note 2, Significant Accounting Policies, in the notes accompanying in our annual report on Form 10-K for the fiscal year ended December 31, 2024 and Part 1, Item 3 —  "Quantitative and Qualitative Disclosure About Market Risk" below for more details on our derivative transactions.
Equity in earnings from unconsolidated joint ventures
46
Table of Contents
For the nine months ended September 30, 2025 we recognized equity in earnings from unconsolidated joint ventures in the amount of $10.5 million compared to $11.3 million for the prior period, a decrease of $0.8 million or 7.0%. The decrease was mainly due to the decrease in earnings from Santa Monica Imaging Group, LLC and Greater Baltimore Diagnostic
Imaging compared to the nine months ended September 30, 2024.
Net income attributable to noncontrolling interests 
At September 30, 2025, our consolidated subsidiaries operated 356 imaging centers of which 101 were not wholly-owned and thus a portion of their operating results were attributable to noncontrolling interests. At September 30, 2024, our consolidated subsidiaries included 345 centers of which 98 were not wholly-owned. 
For the nine months ended September 30, 2025, we recognized net income attributable to noncontrolling interests of $25.2 million versus $27.2 million for the nine months ended September 30, 2024, a decrease of $1.8 million.  A decrease in earnings from Beach Imaging Group, LLC and West Valley Imaging was partially offset by increased earnings from Ventura County Imaging Group, LLC and Advanced Radiology at Capital Region, LLC.
As noncontrolling interests only represent a portion of our imaging center business, and excludes our Digital Health segment which generated losses of $23.1 million for the nine months ended September 30, 2025, we do not expect changes in net income attributable to noncontrolling interests to correlate with changes in consolidated operating income or pretax income.
Digital Health Segment
The breakdown of revenue and expenses of the Digital Health segment for the three and nine months ended September 30, 2025 and 2024 are as follows:
In Thousands
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
$ Change
% Change
2025
2024
$ Change
% Change
Statement of Operations
Revenue
$
24,814

$
16,367

$
8,447

51.6

%
$
64,761

$
46,856

$
17,905

38.2

%
     Salaries and Wages
13,068 
7,119 
5,949 
83.6 
%
31,581 
18,632 
12,949 
69.5 
%
     Stock Compensation
2,268 
528 
1,740 
329.5 
%
8,184 
1,755 
6,429 
366.3 
%
     Other operating
8,293 
6,020 
2,273 
37.8 
%
22,614 
18,207 
4,407 
24.2 
%
Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI
5,486 
3,344 
2,142 
64 
%
13,835 
9,977 
3,858 
39 
%
     Depreciation & Amort.
4,479 
2,947 
1,532 
52.0 
%
10,476 
7,727 
2,749 
35.6 
%
(Gain) loss on sale and disposal of equipment and other
33 
(5)
38 
(760.0)
%
(52)
(4)
(48)
1200.0 
%
     Severance
1,090 
33 
1,057 
3203.0 
%
1,258 
77 
1,181 
1533.8 
%
Total operating expenses
$
34,717

$
19,986

$
14,731

73.7

%
$
87,896

$
56,371

$
31,525

55.9

%
Loss from Operations
$
(9,903)
$
(3,619)
$
(6,284)
173.6

%
$
(23,135)
$
(9,515)
$
(13,620)
143.1

%
Other expense
(39)
2,966

(3,005)
(101.3)
%
(32)
5,413

(5,445)
(100.6)
%
Loss before taxes
(9,864)
(6,585)
(3,279)
49.8

%
(23,103)
(14,928)
(8,175)
54.8

%
Income taxes
$
(2,330)
$
(37)
$
(2,293)
6197.3

%
$
(5,311)
$
(346)
$
(4,965)
1435.0

%
Segment net loss
(7,534)
(6,548)
(986)
15.1

%
(17,792)
(14,582)
(3,210)
22.0

%
Revenues for the Digital Health segment increased significantly compared to the prior-year period, primarily reflecting the contribution from the iCAD acquisition and continued growth in our AI and informatics product lines.
For the three months ended September 30, 2025, external revenue represented 59% of total segment revenue, up from 54% in 2024, reflecting a 65% overall increase. The quarter also saw the customer base expand from 477 to 2,042 and procedure volumes increase from 4.9 million to 6.6 million, mainly driven by the addition of iCAD.
47
Table of Contents
For the nine months ended September 30, 2025, results reflect steady organic growth prior to the acquisition and a sharp acceleration in the third quarter following the inclusion of iCAD, highlighting that recent performance was driven primarily by external expansion rather than internal volume increases.
Segment operating expenses increased year over year due to higher engineering and executive headcount, increased stock-based compensation, and higher non-capitalized R&D costs, reflecting continued investment in scaling our platforms for broader deployment. We expect the segment to continue operating at a net loss in the near term as integration of iCAD, Inc. and See-Mode Technologies progresses.
Non-GAAP Financial Measures

We use both U.S. generally accepted accounting principles ("GAAP") and non-GAAP metrics to measure our financial results. We believe that, in addition to GAAP metrics, non-GAAP metrics such as Adjusted EBITDA assist us in measuring our core operations from period to period.
Adjusted EBITDA
Our Adjusted EBITDA metric removes non-cash and non-recurring charges that occur in the affected period and provides a basis for measuring the Company’s core financial performance against other periods.
We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, as adjusted to exclude  income taxes, interest expense, severance costs, depreciation and amortization, non-cash employee stock-based compensation, loss on sale and disposal of equipment and other, non-cash change in fair value of interest rate hedge, other income, non-capitalized research and development expenses related to DeepHealth Cloud OS and Generative AI, lease abandonment charges, and acquisition transaction costs. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or one-time events that take place during the period.

Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and Adjusted EBITDA should not be considered in isolation or as alternatives to net income, or other financial statement data presented in the consolidated financial statements as an indicator of financial performance.  Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation and this metric, as presented, may not be comparable to other similarly titled measures of other companies.
48
Table of Contents
The following is a reconciliation of the nearest comparable GAAP financial measure, net income, to Adjusted EBITDA for the three and nine months ended September 30, 2025 and 2024, respectively.

Three Months Ended September 30,
Nine Months Ended September 30,

2025
2024
2025
2024
Net income (loss) attributable to RadNet, Inc. common stockholders
$
5,417 
$
3,209 
$
(18,055)
$
(2,552)
Income taxes
6,385 
4,335 
3,807 
4,927 
Interest expense
17,355 
19,427 
51,783 
61,776 
Severance costs
1,441 
304 
2,614 
797 
Depreciation and amortization
39,799 
34,979 
111,275 
101,822 
Non-cash employee stock-based compensation
9,041 
4,723 
46,276 
21,369 
Loss on sale and disposal of equipment and other
1,042 
148 
3,168 
735 
Non-cash change in fair value of interest rate hedge
2,371 
6,755 
6,433 
7,429 
Other income
(9,044)
(5,414)
(24,520)
(16,248)
Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI
5,486 
3,345 
13,835 
9,977 
Lease abandonment charges
2,819 
— 
8,330 
— 
Non-cash change to contingent consideration
— 
— 
— 
1,974 
Non-operational rent expenses
621 
1,287 
2,459 
3,119 
Acquisition transaction costs
2,136 
417 
5,109 
417 
Adjusted EBITDA - Total Company
$
84,869

$
73,662

$
212,514

$
204,451

NOTE
Adjusted EBITDA -  Imaging Center
$
81,417 
$
70,433 
$
201,948 
$
194,433 
Adjusted EBITDA - Digital Health Segment
$
3,452 
$
3,229 
$
10,566 
$
10,018 
The following table is a reconciliation of GAAP net income for our Digital Health segment to Adjusted EBITDA for the three months ended September 30, 2025 and 2024, respectively.

Three Months Ended September 30,
Nine Months Ended September 30,

2025
2024
2025
2024
Segment net loss
$
(7,534)
$
(6,550)
$
(17,792)
$
(14,582)
Stock Compensation
2,268 
528 
8,184 
1,755 
Depreciation & Amortization
4,479 
2,947 
10,476 
7,727 
Other operating (income) loss 
33 
(5)
(52)
(4)
Other expense 
(53)
2,966 
(45)
5,414 
Severance
1,090 
34 
1,258 
77 
Income taxes
(2,330)
(36)
(5,311)
(346)
Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI
5,486 
3,345 
13,835 
9,977 
Adjusted EBITDA - Digital Health Segment
$
3,452

$
3,229

$
10,566

$
10,018

Liquidity and Capital Resources
We expect our existing capital resources, anticipated cash from operations and our borrowing capacity under our credit facilities will be sufficient to sustain our operations for the next twelve months and the foreseeable future.

Our principal capital requirements are for the development of new diagnostic imaging centers, the acquisition of existing diagnostic imaging centers and the acquisition of new diagnostic imaging equipment. On a continuing basis, we evaluate various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures 
49
Table of Contents
and joint ventures. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing available under our secured credit facilities or through new equity or debt issuances.
We and our subsidiaries or affiliates may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.
The following table summarizes key balance sheet data related to our liquidity as of September 30, 2025 and December 31, 2024 and income statement data for the nine months ended September 30, 2025 and 2024 (in thousands):
Balance Sheet Data:
September 30, 2025
December 31, 2024
Cash and cash equivalents
$
804,716 
$
740,020 
Accounts receivable
210,548 
185,821 
Working capital (exclusive of current operating lease liabilities)
563,198 
596,158 
Stockholders' equity
1,313,959 
1,133,410 
Income statement data for the nine months ended September 30,
2025
2024
Total net revenue
$
1,492,498 
$
1,352,563 
Net loss attributable to RadNet common stockholders
(18,055)
(2,552)
Sources and Uses of Cash
The following table summarizes key components of our sources and uses of cash for the nine months ended September 30, 2025 and 2024 (in thousands):
Cash Flow Data
September 30, 2025
September 30, 2024
Cash provided by (used in) operating activities
$
214,656 
$
190,494 
Cash provided by (used in) investing activities
(229,925)
(184,257)
Cash provided by (used in) financing activities
79,602 
400,069 
Cash provided by operating activities for the nine months ended September 30, 2025 increased by $24.2 million compared to September 30, 2024 primarily driven by a $4.0 million change in assets and liabilities, primarily due to the timing of payments for accounts payable and accrued expenses.
Cash used in investing activities for the three months ended September 30, 2025 increased $45.7 million compared to the nine months ended September 30, 2024. The increase was primarily due to a $28.7 million increase in purchases of imaging facilities and other acquisitions, $2.7 million increase in equity contributions to and purchases of interests in joint ventures, and a $17.1 million increase in capital expenditures for property and equipment.
Cash provided by financing activities for the nine months ended September 30, 2025 decreased by $320.5 million compared to the three months ended March 31, 2024. Financing activity in 2024 included a public equity offering that generated $218.4 million in net proceeds and a refinancing of the Barclays Revolving Credit Facility that resulted in an additional $167.9 million of cash. In 2025, financing activity primarily consisted of a $100.0 million incremental term loan under the Barclays Credit Agreement, partially offset by repayment of repayments of term loans, notes, and lease payables of $20.7 million. 
Secured Credit Facilities
We maintain secured credit facilities with Barclays and with Truist Bank.  
50
Table of Contents
On June 11, 2025, we entered into Incremental Amendment No. 2 to the Barclays Credit Agreement, pursuant to which Barclays, as lender, provided an additional $100.0 million of incremental term loan borrowings under our existing senior secured term loan facility, all other terms remained the same.  $1.0 million recognized as discount and deferred finance cost.  Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.  Pursuant to the Second Amendment, we are  required to make quarterly principal payments of approximately $2.4 million, compared to $2.2 million prior to the amendment.
On November 26, 2024, we entered into Amendment No. 1 to the Barclays Credit Agreement (the “First Amendment”) with the Barclays Bank Plc and the lenders and financial institutions named therein.  Pursuant to the First Amendment, the interest rates on the term loans and revolving credit facility provided under the Restated Credit Agreement have been reduced by 0.25%.
On April 18, 2024, we refinanced our Barclays Revolving Credit Facility, replacing the prior facility with an $875.0 million term loan and a $282.0 million revolving credit facility.

The refinance transaction reduced our interest rates on the Barclays Term Loan and revolving credit facility and extended the maturity date for the term loan to April 18, 2031 and for the revolving credit facility to April 18, 2029.

The new term loan calls for quarterly principal payments of $2.2 million, compared to $1.8 million under the prior credit facility.

Our condensed consolidated balance sheets at September 30, 2025 include $1,090.1 million of total term loan debt (exclusive of unamortized discounts of  $12.8 million) in thousands: 
Face Value
Discount
Total Carrying
Value
Barclays Term Loan
$
963,559 
$
(12,319)
$
951,240 
Truist Term Loan
126,562 
(528)
126,035 
Total Term Loans
$
1,090,121 
$
(12,847)
$
1,077,274 
At September 30, 2025, we had no borrowings under our Barclays or Truist revolving credit facilities.  After reserves for outstanding letters of credit of $7.0 million, we had $275.0 million available for borrowing under our Barclays Revolving Credit Facility and $50.0 million available under our Truist revolving credit facility.
Please see Note 6, Credit Facilities and Notes Payable in the notes accompanying our financial statements included in this report for more information on our secured credit facilities.
ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk
Foreign Currency Exchange Risk:

We are exposed to foreign exchange risk with respect to revenues and expenses denominated in the Pound Sterling, Euro, Canadian Dollar, Hungarian Forint and Indian Rupee. We provide radiological services in the United Kingdom, conduct AI operations in the Netherlands, and maintain research and development centers in Canada, Hungary and India.  We do not have any foreign currency exchange contracts to mitigate this risk. At September 30, 2025, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against these currencies, would have resulted in an annual increase of approximately $0.4 million in operating expenses. 
Interest Rate Sensitivity
: 
Our debt instruments, including borrowings under our Barclays Revolving Credit Facility and our Truist Revolving Credit Facility, bear interest at variable rates. Accordingly, our interest expense and our earnings are affected by changes in short term interest rates.  
 To mitigate our future floating rate interest expense exposure, we entered into the 2019 Swaps with a locked-in interest rate for one-month Term SOFR of 1.98% for $400 million of notional value. We are liable for premium payments to the 2019 swap counterparties if interest rates are below the arranged rate and receive payments from the counterparties if interest rates exceed the arranged rate. Payments under the 2019 Swaps are settled in cash on a monthly basis. The 2019 Swaps for the $400 million notional amount will expire in October 2025.
 We can elect SOFR or Alternative Base Rate interest options on amounts outstanding under the Barclays Term Loan.  At September 30, 2025, we had $963.6 million outstanding subject to an SOFR election on the Barclays Term Loan.  At September 30, 2025, our effective SOFR interest rate plus applicable margin was 6.45%.  The 2019 Swaps  secure a $1.98% 
51
Table of Contents
SOFR rate for a $400 million notional amount.  After giving effect to our 2019 Swaps, we had $563.6 million outstanding under the Barclays Term Loan that is unprotected by the 2019 Swaps at September 30, 2025.  Consequently, a hypothetical 1% increase in the SOFR rates under the Barclay's credit facility would result in an increase of $5.6 million in annual interest expense and a corresponding decrease in income before taxes.  The 2019 Swaps will mature in October 2025.
We can elect SOFR or Base Rate interest rate options on amounts outstanding under the Truist Revolving Credit Facility. At September 30, 2025, we had $126.6 million outstanding subject to an adjusted SOFR election on the Truist Term Loan (as defined in the notes to our condensed consolidated financial statements). At September 30, 2025, our effective SOFR rate plus applicable margin was 5.60%.  A hypothetical 1% increase in the adjusted Eurodollar rates under the Truist Revolving Credit Facility would result in an increase of approximately $1.3 million in annual interest expense and a corresponding decrease in income before taxes.
ITEM 4
.  
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of September 30, 2025. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting

There has
 been no change in our internal control over financial reporting during three months ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
52
Table of Contents
PART II – OTHER INFORMATION
ITEM 1.  Legal Proceedings
From time to time we are engaged legal proceedings that arise in the ordinary course of our business. We do not believe that the outcome of any of our current legal proceedings will have a material adverse impact on our business, financial condition and results of operations. 
ITEM 1A.  Risk Factors
For information about the risks and uncertainties related to our business, please see the risk factors described in our Annual Report. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds
None.
ITEM 3.  Defaults Upon Senior Securities
None.
ITEM 4.  Mine Safety Disclosures
Not applicable.
ITEM 5.  Other Information
Rule 10b5-1 Trading Plan.
During the fiscal quarter ended September 30, 2025, none of our directors or executive officers 
adopted
 or 
terminated
 any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement."  
53
ITEM 6. Exhibits
Exhibit
Number
Description
31.1
Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of Howard G. Berger, M.D. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
32.2
Certification of Mark D. Stolper pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101
The following financial information from RadNet, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Changes in Stockholders Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*    This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RADNET, INC.
(Registrant)
Date: November 10, 2025
By:
/s/ Howard G. Berger, M.D.
Howard G. Berger, M.D., President and Chief Executive Officer
(Principal Executive Officer)

Date: November 10, 2025
By:
/s/ Mark D. Stolper
Mark D. Stolper, Chief Financial Officer
(Principal Financial and Accounting Officer)